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ABSTRACT

One in three adults over 85 years old suffer from Alzheimer’s disease (AD) or
other forms of dementia. This already widespread condition is expected to increase
further in both incidence and prevalence in coming years. As a result, the need to
understand the etiology and pathogenesis of dementia becomes ever more urgent. AD,
in addition to its steep cost of care, is the most common form of dementia and the
sixth leading cause of death in the United States. It is a complex disease and its
mechanisms are poorly understood. The more we learn about AD, the more questions
are raised about our current conceptual models of disease. Despite the rapid
advancement of medical technology, reliable and sensitive diagnostic markers to
identify individuals at risk to AD prior onset of clinical symptoms remain in the
developmental phase resulting in inefficient diagnostic procedures. Diagnosis is
further hampered by the heterogeneity of behavioral presentations, cognitive
impairments, and functional statuses observed in AD, all of which may be the result of
varying etiologies. Furthermore, older AD patients often suffer from comorbid
medical conditions that further complicate accurate disease monitoring.
In the absence of an effective AD treatment, it is prudent to apply our current
knowledge of the intersection between AD, cardiovascular disease (CVD), and
cerebrovascular disease to foster efforts to delay the onset of dementia more generally.
The purpose of MANUSCRIPT I is to review our current understanding of the
epidemiology, genetics, and pathophysiology of AD as well as the intersection
between AD and vascular causes of dementia. The epidemiology and shared risk

factors and etiologies for these three disease “clusters” are explored, including shared
genetic contributions and lifestyle, behavioral and environmental risk factors. In this
first publication, we also explore possible mechanistic pathways of AD and the shared
pathophysiology and neuropathological substrates of these three disease clusters.
CVD and cerebrovascular pathology is present for most individuals with AD,
although the converse is not necessarily true. Given this relationship, it is important to
address how early in the disease course those vascular changes can be observed. Such
research is needed to enable early interventions to maintain quality of life in
premorbid AD and reduce the burden of disease. To determine whether there is
cardiovascular alteration in the early stages of AD, MANUSCRIPT II evaluated
electrocardiologic measures of vagal tone for 63 adults (ages 55-75) at rest, during
cognitive testing, and then again at rest. All subjects had multiple risk factors for AD,
and all completed amyloid PET scans (18F-Florbetapir) to determine amyloid
positivity (Aβ+). Cardiac autonomic dysfunction, specifically, an increase in
sympathetic activity and a decrease in parasympathetic activity often referred to as
vagal withdrawal, is prevalent among individuals with AD and is indicative of
impaired autonomic function.
Preclinical AD participants (Florbetapir amyloid PET SUVr ≥ 1.1) did not
consistently show changes in vagal ratio or Respiratory Sinus Arrhythmia (RSA) at
any point during the experiment and they failed to demonstrate the expected response
to the modest stress they experienced during cognitive task performance. Both
changes are directly modulated by both muscarinic and nicotinic cholinergic
autonomic neurotransmission. Because the earliest stages of AD are marked, in part,

by altered function of the basal forebrain cholinergic system, with eventual
degenerative changes including neuronal loss, this result suggests a link between Aβ
aggregation and impaired autonomic cardiovascular function, even in the preclinical
stage of AD.
Another factor that influences the lack of treatment is the absence of a reliable,
affordable, and sensitive diagnostic marker to identify individuals at risk for AD
before the onset of clinical symptoms. One possible marker may be found in the
retina, the retina shares similar embryological origins, anatomical features, and
physiological characteristics with the brain. From as early as the fourth week of
gestation, the eyes, particularly the retinal nerve fiber layer (RNFL) and the optic
nerve, are direct sensory extensions of the central nervous system as their axons
synapse directly with several brain regions. Unlike the brain, however, retinal
neuronal cell layers can be non-invasively visualized through high-resolution optical
methods such as optical coherence tomography (OCT) allowing for the precise
segmentation and measurement of these cell layers. For MANUSCRIPT III, more
than 15 years of literature with inconsistent findings on the relationship between the
morphology of retinal neuronal layers and AD were reviewed. Most papers reported
RNFL and ganglion cell layer (GCL) thickness to be significantly reduced in cross
sectional studies of patients with mild cognitive impairment (MCI) and mild to
moderate AD. For the first time, this Manuscript explores within-subjects longitudinal
change in retinal morphology during the preclinical stage of AD for all retinal
neuronal layers. For this manuscript, fifty-six older adult participants (mean age =
65.36 years) from the previous manuscript completed Spectral Domain-OCT retinal

imaging at baseline. Twenty-seven months later, they completed the same exams as
well as an 18F-Florbetapir PET imaging and cognitive testing.
We observed a decrease over time in macular RNFL, outer nuclear layer and
inner plexiform layer volumes in preclinical AD relative to controls. While the
macular region of the retina is physiologically very active in healthy normal eyes, this
region might have diminished activity in the preclinical stage of AD. This thinning
could be due to either demyelination or loss of axons in the RNFL, both of which
suggest the possibility of future degenerative changes to the cell bodies in the GCL
followed by progression to deeper neuronal layers. Volume loss in the RNFL, during
the preclinical stage, is not related to performance on measures of episodic memory or
problem solving. However, this retinal change does appear to be modestly related to
relative decrements in performance on a measure of audiovisual integration efficiency
that has been recently advanced as a possible early cognitive marker of mild cognitive
impairment.
In order to tie together the findings of relative changes in cardiovascular
function and retinal morphological changes in preclinical AD, we decided to utilize
optical coherence tomography angiography (OCTA), a new technology that makes it
possible to measure retinal vascular flow. Recently, a reduction in vascular bed
complexity in MCI and AD relative to healthy controls was reported by using a fractal
dimension (Df) approach to summarizing OCTA imaging results. In MANUSCRIPT
IV, forty-eight adults (mean age = 68.76 years) from the same sample of participants
had retinal OCTA images captured using an AngioVue system (Optovue, Fremont,
CA, USA). The Df was measured in linearized images of the superficial vascular

plexus (SVP) to determine the space-filling linear extension of the large vessels. Our
findings suggest that individuals at high-risk for preclinical AD have less density and
complexity of retinal microvascular networks in the SVP of the macular region (the
same region in which structural changes were observed in Manuscript III) than healthy
controls. Reduced vascular density in the SVP likely leads to degradation in blood
flow throughout the other parts of the retina and therefore might directly contribute to
continued axonal loss as well as future GCL thinning in AD. Retinal vascular
distribution and blood flow were found to be altered during the earliest stages of AD
suggesting a potential cost-effective and non-invasive marker for preclinical AD.
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PREFACE
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Assessment & Disease Monitoring, published in issue 7 pages 69-87 in 2017. DOI
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Manuscript II: Manuscript format following Journal of Alzheimer’s Disease,
published in issue 59 pages 1057-1065 in 2017. DOI 10.3233/JAD-170217; IOS Press.
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Assessment & Disease Monitoring, published in issue 10 pages 196-209 in 2018. DOI
10.1016/J.DADM-2018.01.003
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Abstract
As the population ages due to demographic trends and gains in life expectancy, the
incidence and prevalence of dementia increases, and the need to understand the
etiology and pathogenesis of dementia becomes ever more urgent. Alzheimer’s disease
(AD), the most common form of dementia, is a complex disease, the mechanisms of
which are poorly understood. The more we learn about AD, the more questions are
raised about our current conceptual models of disease. In the absence of a cure or the
means by which to slow disease progress, it may be prudent to apply our current
knowledge of the intersection between AD, cardiovascular disease, and
cerebrovascular disease to foster efforts to delay or slow the onset of AD. This review
discusses our current understanding of the epidemiology, genetics, and
pathophysiology of AD, the intersection between AD and vascular causes of dementia,
and proposes future directions for research and prevention

Keywords
Alzheimer’s disease; Cardiovascular disease; Cerebrovascular disease; Vascular
contributions to cognitive impairment and dementia; VCID; Dementia; Risk factors
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Research-in-Context

Systematic Review: The authors conducted online searches for all the relevant
literature describing the relationship between Alzheimer’s disease (AD),
cardiovascular (CVD) and cerebrovascular diseases (CBVD). A thorough review of
common epidemiology, risk factors, and possible mechanic pathways that might link
these three entities, is provided.

Interpretation: There is a substantial overlap in epidemiologic, genetic, and clinical
literature of shared risk factors for AD and cardio- and cerebro-vascular comorbidities. There is also very substantial overlap in shared mechanistic relationships
between AD and both CVD and CBVD. We suggest that vascular/cerebrovascular
pathology is present for most individuals with AD, although the converse is not
necessarily true).

Future Directions: Further investigation is required to understand the mechanistic
pathways for shared pathology between these two constellations of diseases. Our
group and others are tracking vascular changes in preclinical AD patients.
Epidemiological studies of CVD progression promise new insights on the effects of
subclinical CVD on the brain. Currently ongoing cardiovascular prevention trials
impacting dementia risk will provide substantial insight into the possibility of delaying
the onset of AD.
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General Introduction

One of the greatest advancements of health in the 20 th century was an increase
in average life expectancy by 30 years [1]. Today, people aged 85 and older are the
fastest growing segment of the population and this has led to a new set of problems for
modern healthcare as the elderly are the most susceptible to disease and disability.
One in three adults over 85 years old suffer from Alzheimer’s disease (AD) or other
forms of dementia [2], the prevalence of which is estimated to increase dramatically
over the next 40 years unless preventive measures are developed [3]. AD is currently
the sixth leading cause of death in the United States and the cost of the disease is high.
Approximately $236 billion will be spent on AD during 2016 calendar year overall,
including patient care and caregivers’ lost wages [4].
Despite the global increase of both incidence and prevalence of AD, it is the
only leading cause of death that we are currently unable to prevent or cure [5]. The
remarkable heterogeneity of risk factors, etiologies, and neuropathologic processes
associated with AD make it especially challenging for development of new treatments
to slow disease progression [4,6]. Fortunately, a number of experimental therapies are
currently in development. These are aimed at mechanisms including
neurotransmission regulators, tau-based therapies, amyloid-β based strategies,
intracellular signaling cascade modulators, oxidative stress reductors, mitochondrial
target therapy, cellular calcium homeostasis modulators, and anti-inflammatory
therapies [7,8,9,10,11]. It is possible that the heterogeneity of behavioral presentations,
cognitive impairments, and functional status observed in AD is due to its potentially
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varied etiology [12]. Adding to this complexity, older adults with AD typically
present with comorbid medical conditions that further complicate accurate disease
monitoring [13]. The current dominant AD models are insufficient to account for the
complexity of biologic processes, polygenic, and epigenetic factors at work [14]. As a
result, key opinion leaders have suggested that the field would benefit from the
development of new conceptual models of AD [14]. The purpose of this review is to
explore the complex relationship between AD, cardiovascular disease (CVD) and
cerebrovascular disease (CBVD). Recent reports that question the strength of the
association between these disease entities will be reviewed and recommendations will
be made for additional research questions to more precisely characterize causal links
between AD, CVD, and CBVD.

Shared Genetic Contributions to AD and Cardiovascular Disease.
The genetic contribution to AD risk is complex. Three familial autosomal
dominant genes associated with early onset disease have been discovered (PSEN1,
PSEN2 and APP) [15,16,17,18,19,20], and these genes may also be associated with
some later onset cases; although together they likely account for less than 10% of all
AD cases [21]. The most predominant type of AD is Late-Onset Alzheimer’s Disease
(LOAD, referred to herein as AD), which affects adults in their sixth to eighth decade
of life. While many genetic risk factors for AD have been studied, a definitive
genotype that causes (late onset) AD has not yet been identified [22]. Thus far, few
genetic markers have been linked to both risk of AD and CVD or CBVD risk. The
ε4 allele of the Apolipoprotein E (APOE) gene is a risk factor for both AD and CVD.
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Over the past two decades, numerous studies have shown that individuals who carry at
least one copy of the ε4 allele have an increased risk for AD compared to those
without the ε4 allele [23,24,25,26] and ε4 carriers with AD have lower blood levels of
ApoE [27]. Low plasma levels of ApoE protein have been found to increase the risk
of AD independent of APOE genotype [28].
Two polymorphisms (rs1801133, rs1801131) in the methylenetetrahydrofolate
reductase (MTHFR) gene correlate with elevated levels of plasma homocysteine and
appear to be associated with AD and vascular contributions to cognitive impairment
and dementia (VCID) [29,30]. High plasma homocysteine levels have been identified
as a risk factor for VCID in a Northern Irish population [29]. Mutations in the MTHFR
gene were found to increase the risk of AD by 2.5 fold and VCID by 3.7 fold in an
Asian population [30].
Beyond APOE and MTHFR, few other genes have been identified to
significantly increase the risk of both AD and CVD. Genetic associations with smaller
effects have been found but a detailed discussion of these is beyond the scope of this
review. Recently, new approaches to evaluating genetic pleiotropy in complex
diseases have been developed [31]. These methods are now being applied to AD [32]
and one recent study demonstrated genetic overlap between AD and CVD by
conditioning on CVD phenotypes including C-protein reactive (CRP) and plasma
lipids [33].
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Shared Risk Factors for AD and CVD
AD and CVD share important cardiometabolic and lifestyle risk factors that
occur in middle-aged to elderly populations. Both AD and CVD are associated with
increasing age, and both are among the leading causes of death. The primary causes
of CVD are coronary heart disease (CHD), hypertension, stroke, and heart failure.
These diseases are frequently interconnected and share an underlying pathology of
atherosclerosis. All known risk factors for atherosclerosis have been the focus of
studies to identify modifiable risk factors for AD. Researchers from the Framingham
Heart Study [34,35] developed a composite measure of general cardiovascular risk, the
Framingham Cardiovascular Risk Profile (FCRP), derived by evaluating one’s age,
gender, diabetes, smoking, treated and untreated systolic blood pressure (SBP), total
cholesterol, and high density lipoprotein (HDL) cholesterol [36]. In addition to
increased risk of CVD, an elevated FCRP score on has been related to markers of
abnormal brain aging, such as smaller brain volume and increased white matter
hyperintensities in brain imaging exams [37]. High FCRP scores are associated with
worsening of cognitive abilities, both in cognitively intact subjects and in mild
cognitive impairment (MCI) patients [38] and is a reliable predictor of progression
from MCI to AD [39]. Other scores developed from Framingham, the Framingham
Stroke Risk Profile and the Framingham Coronary Heart Disease Risk Score, have
been similarly associated with cognitive change over time, incident cognitive
impairment, and dementia [35,39,40,41,43,44]. These risk models are similar to one
developed specifically to assess dementia risk, the Cardiovascular Risk Factors Aging
and Dementia (CAIDE) risk score [45,46,47]. Common elements across scores are:
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blood pressure, cholesterol, and diabetes. Below, we review elements of these risk
scores as they relate to both CVD and AD.

Hypertension /Hypotension
Chronic hypertension, a common risk factor for CVD, causes a thickening of
vessel walls, reduced vessel elasticity and the narrowing of the lumen, especially in
small vessels [48,49]. These sequelae result in reduced cerebral blood flow, a
prominent step in the pathophysiology of both AD and CVD. Chronic hypertension
also compromises blood-brain barrier (BBB) integrity, leading to both cerebral edema
and the introduction of systemic elements into the brain parenchyma [50].
Hypertension recorded 15 years prior, has been associated with smaller brain volumes
in areas typically affected by AD such as the hippocampus [51]. Our group has
observed that an increased resting-state cardiac rate pressure product (RPP) as a
surrogate of myocardial oxygen use, has a small to moderate correlation with
neocortical amyloidosis in midlife adults with preclinical AD [52].
Epidemiological studies have shown that hypertension is risk factor for
dementia [53,54, 55,56,57] but the association is complex [58]. Studies have found
that the risk of dementia and AD may vary in strength and direction according to the
age of onset [55,56,59,60]. Further complicating these findings, several studies have
demonstrated that antihypertensive drugs can reduce the risk of AD [61,62,63,64,65].
Diuretic, angiotensin receptor-1 blocker, or angiotensin-converting enzyme inhibitor
use in the Ginkgo Evaluation of Memory Study, was associated with a reduced risk for
MCI and AD [62]. Among 2,197 participants from the Honolulu-Asia Aging Study
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who were dementia free at baseline, beta-blocker users experienced a 31% lower risk
of developing new cognitive impairments of any cause, compared to those with other
antihypertensive or no antihypertensive use [63]. Taken together, these findings
suggest that methods to effectively lower BP in midlife, e.g., lifestyle changes or
medications, should help retain or improve cognitive function by reducing the risk of
AD and/or VCID.
Conversely, there is evidence demonstrating that hypotension in late life is closely
associated with a higher risk of AD. The Bronx Aging Study [66] followed a healthy
cohort of older adults aged ≥75 years over a median follow up of 6.7 years.
Participants with diastolic blood pressure (DBP) <70 mmHg were twice as likely to
develop AD as those with DBP >90 mmHg, and this risk was even higher for subjects
with persistently low DBP. Interestingly, there was no such relationship for SBP, and
the association between diastolic hypotension and AD was specific; no such
association existed for VCID. A pooled analysis of data from the Rotterdam Study (N
= 6,668) and the Gothenburg H-70 Study (N = 317) found baseline diastolic
hypotension was associated with higher risk of AD and/or VCID over an average of
2.1 years of follow-up, and that the risk was more pronounced in antihypertensive
medication users [57]. Another population-based study (N = 599, mean age 83.5
years) similarly revealed that lower DBP and SBP were associated with a higher
incidence of AD [67]. Extremely low DBP (≤65 mmHg) produced an adjusted relative
risk of 1.7 (95% CI 1.1-2.4) for AD in a prospective study of 1,270 individuals aged
75-101 years [68]. Finally, a meta-analysis of 20 population based studies revealed
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that a decline in DBP in later life may contribute to diminished cerebral perfusion, and
the subsequent ischemic state may lead to increased cerebral Aβ accumulation [69].

High Cholesterol
Cholesterol metabolism plays an important role in the central nervous system
(CNS), as the brain is a cholesterol rich organ, comprising 25% of the body’s
cholesterol [70]. Studies have indicated that lipoprotein lipase, an enzyme that
hydrolyzes triglycerides, may be involved in the biological basis of both AD and CVD
(e.g. essential hypertension, CHD) [71,72,73] through its interaction with brain
lipoproteins and modulation of cholesterol homeostasis in neuronal cells [74].
Apolipoprotein E is crucial for the catabolism of triglyceride rich lipoprotein
components and for cholesterol transport [75] Cholesterol supplied as a lipoprotein
complex, such as HDL is critical for the maturation of synapses and the maintenance
of synaptic plasticity [76,77]. Cholesterol levels influence the clearance of Aβ and the
formation of neurofibrillary tangles through action at the lipid rafts located in neuronal
membranes.
Outside the brain, atherosclerosis is a frequent consequence of high cholesterol
and is an important risk factor for ischemic cerebrovascular disease [78]. The
contribution of atherosclerosis, a frequent consequence of high cholesterol, is an
important risk factor for ischemic cerebrovascular disease [78]. APOE Ɛ4 carrier
status is both a risk marker for AD and CVD. In the Rotterdam Study, APOE Ɛ4
carriers with atherosclerosis frequently had co-morbid AD and more frequent comorbid VCID [79,80].
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Elevated total serum cholesterol levels have been associated with MCI and AD
risk in some studies [81,56]. Others have found that the association between
cholesterol and AD is complex [82,83]. Similar to hypertension, the risk of dementia
associated with high cholesterol may be influenced by the timing and duration of the
condition, as well as its treatment. One reason for this complexity is that plasma
cholesterol levels do not reflect cholesterol concentrations inside the BBB. The
association between high cholesterol and increased risk of AD has resulted in a
number of studies testing the hypothesis that statins, which play a role in cholesterol
reduction, might prevent the onset or progression of AD. Early epidemiological
studies in this area predicted that statins could reduce the incidence of AD by as much
as 70% [84,85,86]. However, whether statins and resultant reduction of cholesterol
cause a significant reduction in AD pathology is still unclear. More recent results of
large-scale randomized controlled trials suggest no significant clinical benefit of
statins in participants at-risk for AD [87,88].

Diabetes Mellitus
Diabetes mellitus (DM) is a complex metabolic disorder that is closely
associated with changes in cognition as well as other risk factors for accelerated
cognitive decline and dementia, such as hypertension and atherosclerosis [89]. DM
occurs when there is a prolonged period of high blood glucose levels, or
hyperglycemia. There are two types of DM, Type 1 is congenital and caused by
insulin deficiency, and Type 2 is acquired and caused by insulin resistance.
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Although there are points of intersection between the molecular mechanisms
underlying diabetes and AD, the exact mechanism of how insulin inefficiency
increases the risk of AD remains unknown. The literature is currently separated into
two different schools of thought [90]. One follows from Rotterdam study findings,
suggesting that the excess of insulin or glucose from type 2 diabetes mellitus (T2DM)
leads to AD. This is based on studies demonstrating that AD patients have
significantly higher levels of insulin and glucose than healthy controls [91,92,93]. A
second school of thought suggests that insulin deficiency, either due to the relative
deficiency that results from insulin resistance in early stages of T2DM, or absolute
deficiency that occurs when beta cell dysfunction occurs in full-blown T2DM, causes
AD by impairing insulin’s ability to perform its roles in the brain [94,95,96,97].
In addition to these two theoretical approaches in the literature, some have
suggested the term “Type 3 diabetes” was coined to account specifically for the
underlying abnormalities associated with concurrent AD-type neurodegeneration and
diabetes [98]. These researchers maintain that AD and diabetes share common
pathophysiology, and therefore therapeutic regimes aimed at diabetes treatment and
amelioration could be effective for treatment of AD [99].
A recent meta-analysis demonstrated a strong link between diabetes and VCID
[100]. Findings from the Rotterdam study demonstrated a nearly two-fold risk of AD
and suggest that DM increases the risk of dementia by 1.9 fold, and that DM patients
treated with insulin were at even greater risk (4.3 fold) [101]. Multiple populationbased studies have shown that patients with DM exhibit an increased risk of
developing AD [102, 103, 104, 98]. The authors of one such study concluded that
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39% of AD in a large sample of elderly subjects was attributable to hyperinsulinemia
or DM [105].
As with other CVD risk factors, treatment for diabetes has been shown to alter
the risk of AD. Metformin has been shown to reduce the risk of AD and is currently
being studied in clinical trials with promising preliminary results in MCI patients
[106]. A large clinical trial is currently underway to evaluate the efficacy of low dose
pioglitazone as a preventive treatment for MCI due to AD [107]. Other studies have
considered the use of intranasal insulin, which has been shown to exert a modest effect
on memory performance in AD patients [108,109,110,111].

Lifestyle, Behavioral, and Environmental Risk Factors
High fat diets and sedentary lifestyles have led to a growing incidence of
obesity, dyslipidemia, high blood pressure and metabolic syndromes [112, 113,114].
These conditions are precursors to, or develop along with atherosclerosis, diabetes,
CVD, and an increased risk for AD [115]. Major depression has also been linked to
both AD and CVD and more recently environmental exposures such as fungal
pathogens and pollution have been under investigation for ties to both AD and CVD.
Below, we review the literature that explores the obesity, aerobic exercise, smoking,
major depression, and exposures such as fungal pathogens and air pollution, each as
shared risk factors for both CVD/CBVD and AD.
Obesity
The mechanism by which obesity influences cognition and AD risk remains
under active investigation. One mechanism may be through vascular pathologies, or
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there may be hormonal, genetic, or inflammatory processes at work [116]. The
Framingham Heart Study reported a marked impairment of cognitive function in
patients with obesity compared with non-obese counterparts [117]. Epidemiological
studies have shown associations between obesity and increased AD risk in females
[118,119] although other studies have found increased risk of dementia for both
genders [59]. Pooled results from 11 studies [120] demonstrated that the strength and
direction of the association varies over the life course. The association between body
mass index (BMI) and later onset of AD appears to be stronger when BMI is measured
at midlife [121] than when BMI is measured in later life [118,122]. Although they
frequently co-occur, DM and obesity are widely accepted as important independent
risk factors for AD [123].

Aerobic exercise and physical fitness
In contrast to metabolic syndromes, aerobic exercise and healthy lifestyles
have been shown to reduce the incidence of both CVD and AD in observational
studies. Cardiovascular diseases have become very common as communities and
individuals attain more wealth and pursue more sedentary lifestyles [123]. Aerobic
exercise promotes brain vascularization and may reduce vascular risk factors and
improve cognitive function [124,125,126,127]. Randomized controlled trials with as
little as six months of exercise training lead to increased hippocampal volume and
improved performance on spatial memory and executive function tasks [128,129].
Aerobic exercise also up-regulates brain derived neurotrophic factor (BDNF), which
augments plasticity in the hippocampus [130,131].
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Epidemiological studies have demonstrated reduced risk of cognitive decline
and dementia as a function of activity levels [132,133,134] and studies have shown
increased gray and white matter volume in brains of participants assigned to aerobic
training [135] or those with higher levels of self-reported exercise [136]. Recent
meta-analysis of clinical trials of exercise interventions in dementia patients
demonstrated positive effects [137]. A recent prevention trial of an exercise
intervention in sedentary older adults failed to find a significant effect on cognitive
function [138], however secondary analyses found significant improvement in
cognitive function among the subset of participants who were diabetic [139].
A related measure of physical fitness is heart rate variability (HRV) on
continuous electrocardiography recordings. HRV is usually relatively high for those
who exercise frequently [140], as well as for young and healthy individuals. Aging
and poor physical fitness are associated with an impairment of cardiac vagal function
[141], and HRV is lower for those with relatively diminished parasympathetic tone
[142], including those with CVD [143]. Vagal tone, the ability of the vagus nerve to
rapidly regulate cardiac output, accounts for a substantial portion of HRV. Vagal tone
can be quantified via respiratory sinus arrhythmia (RSA), which measures the slight
ebb and flow in heart rate that occurs during the respiratory cycle. RSA is higher in
older adults who demonstrate better performance on tasks of verbal episodic memory,
a cognitive domain that is typically impaired with the onset of AD [144].
In Table 1, we provide a listing of evidence-based interventions for the
treatment of CVD, discussed in the sections above, and how these specific
interventions have been explored in the treatment of AD.
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-----------------------------------------------------------Insert Table 1 About Here
------------------------------------------------------------Smoking
There is some evidence to suggest that long-term cigarette smoking is an
independent risk factor for AD, CVD and CBVD [145,146,147]. Smoking increases
total plasma homocysteine, an independent risk factor for stroke, cognitive
impairment, AD and other dementias [148,149,150,151]. Smoking accelerates
atherosclerosis [142] and can cause oxidative stress, which is associated with
excitotoxicity, leading to neural death [152]. A dose-response relationship between
smoking and dementia risk has been documented [153] and AD risk among smokers is
increased in APOE ε4 carriers [101,154]. A meta-analysis of studies performed in the
1990s and early 2000s revealed that relative to non-smokers, current smokers had
increased risks of 1.79 fold (95% CI 1.43–2.23) for AD and 1.78 fold (95%CI 1.28–
2.47) for VCID [155]. A more recent systematic review confirmed the previous
findings with increased risks of 1.59 fold (95% CI 1.15–2.20) for AD and 1.35 fold
(95%CI 0.90–2.02) for VCID [156].

Major Depression
A history of major depression is another shared risk factor for AD and CVD.
Late-onset depression is often associated with AD, and AD patients with episodes of
major depression over their lifetimes show greater hippocampal pathology at autopsy
[157]. Evidence exists to suggest that the two disorders may share common etiological
substrates [158, 159]. Chronic, untreated major depressive disorder is associated with
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the selective loss of noradrenergic cells in the locus coeruleus [160,161] and the loss
of dorsal raphe serotonergic nuclei [162], both of which have been demonstrated in
AD. Major Depression is now widely acknowledged to be a CHD risk factor, based on
work demonstrating that psychosocial factors such as chronic dysphoria, anxiety,
perceived loss of locus of control and perceived stress are strongly predictive of
incident myocardial infarction [163]. Nearly one of five patients with CVD suffers
from major depressive disorder [164]. Depression may be directly linked to cerebral
ischemia secondary to reduced cerebral blood flow [164] and is associated with an
increased risk of recurrent stroke in patients with VCID [165]. CVD has been
proposed as a mediator of the relationship between major depression and AD [166].
Hyperhomocysteinemia has been demonstrated in both AD and major depression
[167,168]. Adding to this already complex picture, heightened homocysteine levels
are found in CVD [149], indicating a potential shared mechanism in AD, CVD, and
major depression. The exact nature of the downstream effects of this mechanism
requires further research.

Fungal pathogens
More recently, fungal macromolecules have been identified as a potential
pathophysiological substrate of both AD and CVD. The presence of fungal cells in
different sizes and hyphae inside capillaries and other blood vessels in some AD
patients suggests that fungal infections can be detected in the neurovascular system
and may, in some cases, explain the vascular pathology frequently detected in AD
patients [169,170]. One study showed that Aβ peptide, a cardinal feature of AD
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pathology, could exert antimicrobial activity for at least eight different
microorganisms, suggesting a brain with AD could specifically induce Aβ-mediated
inflammatory activity against Candida albicans [171]. Unfortunately, many
macromolecules with antimicrobial activity have been shown to be cytotoxic towards
vascular smooth muscle cells [172], and Aβ is no exception [173]. There is also
association of AD with various types of spirochetes, and C. pneumonia [174].
However, thus far, to our knowledge, the only documented common fungal or
microbial pathogenic link between AD and CVD is Candida albicans. The
pathophysiological link between pneumonia and acute cardiovascular events has been
explained via the long-lasting infection hypothesis, which implicates microorganisms
in atherosclerosis [175].

Air pollution
Chronic exposure to air pollution, which is associated with reduced HRV, is
another environmental factor that is associated with both CVD and AD. Specifically,
long-term exposure to high ozone and high particulate matter in the air leads to
increased risk for obesity, metabolic syndrome [176], and a host of CVDs [177}
including myocardial ischemia and infarction, heart failure, arrhythmias, stroke, and
increased cardiovascular mortality [178]. Recently, a dose-response relationship was
found between longitudinal exposure to high concentrations of atmospheric particulate
matter <10 μm in diameter and significantly increased risk of AD and VCID in
industrial regions of Taiwan [179].
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Co-occurrence of AD and Cerebrovascular diseases
Cerebrovascular disease (CBVD) is a generic term from a heterogeneous set of
insults to the cerebral vasculature, and such insults often lead to various cognitive
impairment(s). CBVD insults include, but are not limited to, microvascular
degeneration (with looping, twining and braiding vessels) [180], periventricular
venous collagenases, and vascular tortuosity [181]. These microvascular changes all
cause impaired cerebral perfusion [182]. Some studies have shown a correlation
between capillary length per brain volume and reduction of glucose utilization [183].
Intracerebral hemorrhages due to Aβ accumulation within vessel walls can contribute
to AD pathology [184]. This leads to increased incidence of infarcts in the brain tissue
innervated by this system [185]. Collectively, these conditions are considered among
the causes for VCID. VCID (vascular contributions to cognitive impairment
and dementia) refers to a progressive worsening of cognitive functions and memory.
VCID is due exclusively to vascular disease within the brain [186]. It is often very
difficult to distinguish AD from VCID as they appear very similar on clinical exam.
VCID patients often present with episodic memory impairments, word-finding
difficulties, disorientation to time, and subtle executive deficits [187]. Thus, a
differential diagnosis is aided by careful neuropsychological examination in
conjunction with appropriate biomarker studies [188].
In the United States, CBVD is the leading cause of disability in adults and the
third leading cause of death [189]. CVD often plays a direct causal role in
cerebrovascular events, as CBVD often results from a lack of blood flow to the brain.
Various CBVD pathologies are observed in 60 to 90% of AD patients, including white
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matter lesions, micro-infarcts, hemorrhages, microvascular degeneration and cerebral
amyloid angiopathy (CAA) [75]. CAA is the abnormal deposition of a congophilic
material in meningeal and cerebral arterioles. The prevalence of CAA is high in AD
and often progresses in severity causing vessel rupture [190]. Atherosclerosis, a
common cause of CBVD, can lead to cerebral infarction or stroke, and disabling
cognitive impairments in late life [191]. Many large population-based epidemiologic
studies have provided strong support for the relationship between AD and
cerebrovascular changes. One such study examining two large cohorts of AD patients
found a strong relationship between AD and cerebral atherosclerosis, such that the
presence of atherosclerosis was associated with worse cognitive performance in AD
[192]. The Framingham Heart Study found that a lower cardiac index was associated
with increased risk of AD [193]. These findings suggest that age-related changes in
systemic hemodynamics may contribute to the pathogenesis or exacerbation of
amyloid deposition, subsequent neuronal injury, and vascular pathology [193].
Similar findings have been reported for other large epidemiologic studies, including
the Pittsburgh Cardiovascular Health Study [194] and the Prospective Population
Study of Women in Gothenburg, Sweden [195]. Likewise, the Atherosclerosis Risk in
Communities (ARIC) study found a high prevalence of MRI-detected cerebral
abnormalities, related to cognitive functioning, that might reflect preclinical AD [196].
As described above and across a large body of published literature, VCID can
manifest solely as a result of CBVD events, such as hemorrhagic or ischemic strokes,
or by the accumulation of multiple ischemic events. However, it remains unclear
whether AD occurs in the absence of any vascular pathology, or whether CVD and
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CBVD changes are mechanistically related to the fundamental pathology of AD. Two
separate imaging studies have recently cast doubt on the interdependence of AD and
vascular pathologies [197,198]. The studies suggest that AD-related amyloid burden
and CBVD independently affect cognitive impairment, as there was no correlation
between the images comparing specific neuroanatomic coordinates of both
amyloidosis (positron emission tomography (PET) PIB ligand binding) and white
matter hyper intensities (WMH) with structural magnetic resonance imaging (MRI).
In a study of 251 cognitively impaired subjects, Ye and colleagues found that PiB
retention ratios were associated with both hippocampal atrophy and memory
impairments and, conversely, the WMH imaging was more strongly associated with
frontal cortex thinning and executive dysfunction. The authors concluded that the
effect on cognition for individuals with both pathologies was additive and not
synergistic, thus, the impact of AD and CVD pathologies on cognition are mediated
through independent mechanisms [198]. Vemuri et al (2015) evaluated MRI and PET
images from 393 cognitively normal participants, aged 70 to 90 from the Mayo Clinic
Study of Aging and showed that for subjects with both vascular and amyloid
pathologies, the effect of both pathologies on cognition was additive and not
synergistic [197]. Both Ye, and Vemuri and colleagues have put forward similar
arguments, but they are based on a single MRI imaging marker of CBVD. However,
as we outline below, cardio- and cerebrovascular pathologies are highly complex
clusters of biological processes that share many points of mechanistic links to AD.
These two recent imaging studies stand as outliers within a large body of literature
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suggesting that although VCID may frequently occur in the absence of AD, the
converse is not necessarily true.

AD, CVD, & CBVD: Shared Pathophysiology and Neuropathological Substrates
AD, CVD and CBVD, primarily affect the same at-risk population who share
many common risk factors. All three diseases may independently and/or interdependently lead to debilitating, unremitting and progressive changes in cognition.
The direct causal relationship between vascular and cerebrovascular insults, and
dementia or apoplexia, was described over three centuries ago by Thomas Willis
[199]. Medical practitioners generally considered dementia to result from vascular
insults. As early as 1833 Lobstein used the term “dementia arteriosclerotica”
attributing the nature of the disease to a vascular origin [200]. A causal link between
other non-vascular brain disease states and dementia was not well described until the
latter half of the 19th century. In 1871, Charles Darwin received a letter from the
director of England’s largest lunatic asylum, Dr. James Crichton-Browne, who
observed that senile decay was the result of central nervous system disease that was
linked to emotional liability [159]. Thirty-six years later, the initial case report of
Alois Alzheimer’s; described the finding of senile plaques and neurofibrillary tangles
found on post-mortem histopathology exam of a patient who had “ordinary dementia”
and neuropsychiatric symptoms [201].
Prof. Alzheimer presaged the complexity and multi-causality of dementia by
reporting atherosclerosis in the cerebral blood vessels of his 55 year-old patient, for
which he coined the term Alzheimer’s sclerosis [202]. The term AD was reserved for
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the diagnosis of dementia with onset between ages 40 and 90 years, if the other causal
explanations (e.g., vascular causes) of dementia were absent [203]. The National
Institute of Aging (NIA) and the Alzheimer’s Association (AA) revised the diagnostic
and research criteria for AD in 2011, and this re-formulation of the diagnostic
nosology were detailed in three publications that year [204, 205, 206]. According to
the new NIA-AA criteria, a diagnosis of “pre-clinical AD” is based on the presence of
relevant positive biomarkers (e.g., PET amyloid imaging) in conjunction with known
risk factors for the disease (e.g., APOE e4 allele). The identification of individuals in
this stage of prodromal AD is made essentially for research purposes only [204]. MCI
due to AD includes patients with mild cognitive symptoms (impaired performance on
measures of episodic memory function) with positive evidence of the disease from
appropriate biomarker studies [205]. Ultimately, a diagnosis of AD is now based on
criteria that account for recent developments in disease-specific biomarkers, which
allow for confirmation of AD without the need to rely on post-mortem histopathology
[206, 207,208].
Below, we briefly review the major overlapping pathophysiology between
CVD, CBVD, and AD, all of which may be briefly summarized by Table 2.
-----------------------------------------------------------Insert Table 2 About Here
-------------------------------------------------------------

Reduced Cerebral Blood Flow
Normal brain function is dependent on receiving 20% of the cardiac output of
oxygenated blood and both higher and lower blood pressure may reduce this cerebral
blood flow [209]. Hence, impaired cardiac function may subsequently lead to both
24

reduced intracranial blood flow (e.g., as measured within the Circle of Willis) and
ischemia, and this is readily observed in AD patients [210]. Reduced cerebrovascular
reactivity was observed in a study of 18 young adult (mean age 24 years) carriers of at
least one APOE ε4 allele [211]. Suri and colleagues surmise that this lifelong relative
decrease in cerebral blood flow will lead to areas of hypo-perfusion and microvascular
damage; thereby, contributing to aggregation of blood products, endothelial
dysfunction and impaired Aβ clearance [211]. It is of note that the sample size in this
study was small, and further investigation is required to elucidate the nature of the
interaction between cerebral blood flow, APOE status, and AD. A meta-analysis was
conducted to investigate whether the changes in cerebral blood flow velocity and
pulsatility index by Doppler ultrasonography in AD and VCID follow similar patterns.
Both disease states were found to be associated with pronounced disturbances in
cerebrovascular hemodynamics, with VCID patients showing significantly lower
cerebral blood flow [212].
Another factor that may contribute to reduced regional cerebral blood flow is the
observed decrease of endothelial Nitric oxide (NO) synthesis in AD [213]. The
enzyme eNOS is responsible for NO generation, which is important for cardiovascular
homeostasis and acts as a vasodilator involved in the control of vasomotor function
and local blood flow [214]. Endothelial production of NO is important for the
prevention of CBVD, as it mediates protection from stroke by preserving cerebral
blood flow and preventing inflammation, thrombosis and apoptosis [215]. Besides the
CBVD contributions, it can also increase expression of APP and BACE1 consequently
increase Aβ levels [216]. The evolving opinion is that cerebrovascular dysfunction is
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not only present in CBVD, but also a prominent component of neurodegenerative
pathologies such as AD [217].

Aβ deposition
The amyloid cascade hypothesis postulates that neurodegeneration in AD is due to
an abnormal accumulation of Aβ plaques in various areas of the brain [218], and the
neurodegenerative processes in AD are the consequence of the imbalance between Aβ
peptide production and clearance [219]. Recently, Yau and colleagues provided clear
support for targeting Aβ clearance in early AD based on their longitudinal study of 16
patients with an autosomal dominant mutation for early-onset AD. In their study, they
demonstrated that amyloidosis is one of the earliest events in the neuropathology
cascade leading to AD, with the majority of Aβ aggregation occurring before the
progressive structural neurodegeneration and cognitive decline [220].
The abnormal aggregation of Aβ protein in the brain neuropil may lead to either
diffuse plaques and/or concentrated neuritic plaques, with the latter form of deposits
often present in the vicinity of the cerebral microvasculature [221]. The Aβ protein,
with its crystalline molecular structure, infiltrates the vessel walls and compromises
the blood-brain barrier (BBB) [221]. Deposition of Aβ protein within the walls of
cerebral blood vessels also leads to CAA, increasing the risk of cerebral hemorrhage
[75], which is the most common clinical presentation of CAA [222]. In an APP/PS1
transgenic mice study with induced hyperhomocysteinemia, Sudduth and colleagues
showed that congophilic amyloid deposition was decreased in the parenchyma and
significantly increased in the vasculature in CAA. This suggests that CBVD can
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significantly impact Aβ distribution in the brain by vascular deposition, and that such
deposition can induce microhemorrhages and activate neuroinflammation [223]. In an
in vivo study of Sprague-Dawley rats, infusion of solubilized Aβ peptides enhanced
constriction of cerebral and peripheral vessels, contributing to cerebral hypoperfusion
and leading to decreased blood flow and increased vascular resistance [224]. The risk
of both repeated hemorrhagic strokes, as well as ischemic events due to vessel wall
stenosis and oligaemia, increases with continued Aβ accumulation for both CAA and
AD patients. This pathologic cascade leads to medial temporal atrophy, cognitive
decline and progressive brain atrophy [75]. Finally, vascular Aβ deposits observed in
AD have been shown in vitro to induce degeneration of human and murine
cerebrovascular smooth muscle and endothelial cells, resulting in vasoconstriction,
intraluminal thickening, inhibiting angiogenesis, impairing vascular tone and
decreasing total cerebral blood flow [225].

Morphological Changes in the Vasculature
Arterial stiffness can be caused by structural or cellular change within vessel walls,
and amyloid deposition in the vessels leads directly to this pathophysiological process
[226]. The fragmentation of elastin alters the haemodynamics of vessel walls, resulting
in increased systolic pressure by increasing the speed of the arterial wave that arrives
prematurely during systole rather than during diastole [227]. Atherosclerosis also
accelerates arterial stiffness [228], a frequent finding in patients with CVD. Arterial
stiffness is a clear risk factor for cognitive impairment in later life, as it can cause
structural changes in the brain, such as white matter or cortical infarcts and cortical
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brain atrophy [229, 230]. A recent systematic review of this association concludes
that arterial stiffness is related to cerebral small vessel disease and decreased cognitive
function [231].
The deposition of Aβ in arterial vessel walls, and subsequent impediment of
perivascular drainage of Aβ due to the AD pathology, can lead to intracerebral
haemorrhage and an increase of Aβ peptides [75]. These morphological and
architectural changes of the cerebral vasculature, studied in APP23 tg mice, start early
in life. Along with the increase in observable amyloid plaques, there is also increased
atrophy and altered blood flow, suggesting that disrupted microvasculature integrity
can contribute to the progression of AD [232]. However, subtle changes in cerebral
microcirculation are difficult to measure with high precision for the exploration of
longitudinal changes within-subjects associated with increased disease burden. These
subtle morphological changes may be more easily observed in the microvasculature of
the retina. Patients with AD have sparser retinal microvascular networks and other
structural alterations that may mirror pathophysiological events found in the cerebral
microvasculature [233]. Patients with AD show changes in retinal microvasculature,
such as more tortuous retinal vessels and a narrowing of retinal venules [234]. These
retinal vascular changes have been posited to precede the majority of
neurodegeneration that characterizes AD progression [49].

Alterations in Blood-Brain Barrier (BBB) Permeability
The brain vasculature has cellular elements forming a developmental, structural
and functional relationship with the brain tissue termed the neurovascular unit [226].

28

The neurovascular unit has a fundamental role in the broad spectrum of pathologies
underlying cognitive impairment. Neural activity requires a continuous and regulated
blood flow in order to activate neurons, astrocytes and vascular cells through a wide
variety of molecular signals (ions, arachidonic acid, metabolites, NO, adenosine,
neurotransmitters, and neuropeptides) [235]. Specific neuroimaging techniques to
visualize deleterious changes to the BBB are still under exploration. Several studies
have shown that plasma proteins like prothrombin, which are typically excluded from
the CNS, can be found within the microvessel walls and surrounding neuropil in AD
patients, showing that the leakage of the BBB may be frequent in AD [236]. The
vascular abnormalities found in the AD brain, such as alteration in smooth muscle
cells and pericytes, endothelial cell thinning, loss of endothelial mitochondria and
thickening of the vascular basement membrane, all contribute to alterations in BBB
permeability [237]. The end result is a continuous cycle of reduced cerebral perfusion
leading to acceleration of the neurodegenerative process, which further reduces
perfusion.
The changes in BBB permeability lead to an ionic imbalance and accumulation of
toxic metabolic products. As a consequence, synaptic, neuronal and oligodendrital
dysfunction occurs [238], since an intact BBB is crucial for limiting the entry of toxic
products and cells into the brain. Glucose transport across the BBB is also impaired,
and positron emission tomography (PET) studies show reduced regional metabolic
rate in the AD brain [239]. Alterations on the (Na+/K+)-pump function of the BBB
can result in fluid balance impairment, leading to deregulation of regional cerebral
blood flow [240].

29

Aβ accumulation can contribute to the leakage of the BBB [241]. These peptides
spread across a defective BBB contribute to higher oxidative and nicrosative damage,
as well as increased protease activity [75]. Aβ deposition leads to microglial
activation, reactive astrocytosis and a multi-protein inflammatory response [242].
Studies of WT and APOE -/- mice show that BBB permeability increases with age and
a defect in the BBB is exacerbated in APOE -/- mice [243,244]. Additionally, arterial
stiffness results in an uncoupling of the neurovascular unit, and this disruption of the
cerebral microenvironment is likely to contribute to brain dysfunction [245]. The
resulting accumulation of Aβ in the neuropil and vessel walls leads to the activation of
neuroinflammatory response, which plays an important role in BBB disruption [246].
Anatomically, neuroinflammation may lead to transient increases in thickness of
various cortical tissues, as well as at least one neuronal cell layer of the retina in
preclinical stage disease. Snyder et al. (2016) have provided initial evidence to suggest
an increase in the thickness of the retinal inner plexiform layer, in preclinical AD, and
they postulate this volume increase may be partly due to a localized
neuroinflammatory process and/or deposition of amyloid-containing inclusion bodies
within the cell layer. They suggest that this observation may precede a gradual
thinning of neuronal cell layers (e.g., the ganglion cell layer) and the retinal nerve
fiber layer with continued disease progression [247].

Cholinergic neurodegeneration
Postmortem studies have shown reduced activity of choline acetyltransferase,
decreased numbers of nicotinic acetylcholine receptors, and reduced basal forebrain
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cholinergic neurons (particularly in the nucleus basalis of Mynert), contribute to the
oldest model of neurobiologic dysfunction in AD – the “cholinergic hypothesis”
[248,249].
This reduction in cholinergic innervation and activity may result, in part, from a
reduction in noradrenaline release due to Locus coeruleus (LC) neuron loss [250].
There is a strong reciprocal connection between the LC and the prefrontal cortex, and
this area is involved in the mediation of executive functioning, memory and vigilance
[251]. The LC is responsible for exerting an excitatory influence on wakefulnesspromoting nuclei, such as the cholinergic nuclei of the septal area, medial preoptic
area and substantia innominata [252]. Pathological changes in the LC occur early in
AD [253], and this reduction in LC activity likely leads to the common finding of
reduced levels of arousal and alertness in AD patients. The number of LC neurons
projecting to areas such as the hippocampus and the frontal cortex, decline slowly with
normal aging, and this may result in some modest age-related changes in spatial
learning and memory [254].
This structural and functional loss in the LC affects both efferent and afferent
pathways. The LC exerts both direct (via a descending excitatory noradrenergic
pathway) and indirect effects (via modulation of the activity of other premotor
sympathetic nuclei) on preganglionic sympathetic neurons in the intermediolateral cell
collumn [255]. The LC sends efferent inputs to the nucleus tratus solitarius, which is
critical for the modulation of the vasomotor response to changes in blood pressure
through vagal nerve stimulation and autonomic inputs to the heart. The vagal nerve
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provides cholinergic input to increase parasympathetic activity, which decreases heart
rate and lowers blood pressure when needed [256].
The earliest stages of AD are marked, in part, by altered function of the basal
forebrain cholinergic system, with eventual degenerative changes including neuronal
loss [257,258]. We have recently reported that a down-regulation of central
cholinergic neurotransmission appears to be one of the earliest neuropathological
changes in preclinical AD [259], and we have also found that individuals with
evidence of both decreased central cholinergic tone and amyloid aggregation within
the anterior cingulate region show evidence of increased resting cardiac workload at
rest [52]. The aggregation of Aβ plaques in the neocortex, within this specific region
of interest that is part of the central cholinergic system, appears to be directly
associated with increasing cognitive impairment as well as the higher myocardial
oxygen consumption at resting state [52]. In fact, there is a growing body of literature
to suggest a direct link between Aβ aggregation, basal forebrain cholinergic damage,
and diminished cholinergic innervation of cortical blood vessels, leading to the
microvascular pathology that has been documented in the majority of AD cases
[260,261,262,263].We are currently exploring whether indices of phasic vagal cardiac
control, such as resting sinus arrhythmia (RSA) and heart rate variability (HRV) are
also related to cortical amyloidosis in preclinical AD, since both RSA and HRV are
directly modulated by muscarinic cholinergic and nicotinic autonomic
neurotransmission.
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General Discussion

This review is intended to tie together several lines of research on the shared
mechanistic relationships between AD, CVD, and CBVD. The literature that binds
these diseases is both large and confusing. Why is AD so tightly connected to
disruption of the cerebrovasculature and to cardiologic disease? Why do these broad
disease entities share so many risk factors and mechanistic relationships? One
compelling answer to these larger questions may come from the field of medical
anthropology and attempts to study the global distribution of APOE gene alleles across
the human species. The ε4 allele is the ancestral form of APOE [264,265] and is
associated with both higher absorption of cholesterol at the intestinal level and higher
plasma cholesterol levels in carriers. The phenotypic expression of this allele would
likely confer a survival benefit to humans that evolved with limited food supplies and
in harsh weather conditions. Expression of the Ɛ4 allele under contemporary/modern
diet, exercise and environmental conditions, together with the relatively recent and
dramatic increase in human longevity may have now led to the identification of the Ɛ4
allele as pleiotropic, showing susceptibilities for both CVD and AD [265]. Although
this anthropological viewpoint is not universally accepted, nor the focus of the current
review, it affords us an over-arching heuristic model to explain the strong relationship
between CVD, CBVD and AD.
Another question that arises from the frequent co-incidence of AD, CVD, and
CBVD is whether or not they are the end result of shared etiologic mechanisms. If one
supposes a direct, bi-directional causal link between these disease clusters, then all
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cases of CVD and/or CBVD would also demonstrate AD pathology, and we know this
not the case. Rather, we have reviewed a large literature indicating that
vascular/cerebrovascular pathology is present for most individuals with AD but not all
of them. In support of this notion, an autopsy study with the largest cohort to date (N
= 5,715) showed increased prevalence of CBVD and vascular pathology in AD
compared to healthy controls and patients with dementias of non-AD etiologies [266].
So what, then, is the causal nature of the relationships between these diseases?
To answer this question, it is important to determine whether the cognitive effects of
AD and CVD/CBVD are additive or synergistic. This is a topic that continues to elicit
considerable scientific exploration. It is possible that AD and CVD/CBVD contribute
independently to dementia, such that the severity of the dementia is a cumulative
result of two separate pathologies [196]. Alternatively, these disease processes could
be synergistic, such that the pathology of one accelerates the progress of the other.
The majority of the literature reviewed herein supports the model of a synergistic
interaction between vascular/cerebrovascular and neurodegenerative processes early in
disease pathogenesis. This theory is further supported by a reciprocal relationship
between Aβ accumulation and cerebrovascular insult such that Aβ deposition
provokes vascular/cerebrovascular changes [75] and vice versa [267,268]. Clinical
studies demonstrate that even mild cerebrovascular pathology results in reduced
cognitive performance in very early AD [78, 269]. It is possible that both additive and
synergistic processes are affecting cognitive decline at different stages of these disease
processes. This theory is congruous with variability in observational findings based on
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timing, severity, and duration of CVD risk factors. In fact, it has been suggested that
later disease stages of disease could demonstrate a more additive relationship [270].
There is evidence that vascular/cerebrovascular pathology can accelerate the
progression of preclinical AD and speed disease evolution [271,272]. The
relationships between AD and CVD/CBVD are complex, and further investigation is
required in order to discern the exact nature of these relationships at different stages of
disease progression. We suggest that, because AD is so frequently accompanied by
comorbid vascular and/or cerebrovascular symptoms, it is both clinically and
scientifically relevant to consider these pathologies concurrently, regardless of
whether their respective underlying pathologic mechanisms are independent and
additive, or functionally related and synergistic.
We support the widely studied hypothesis that effectively controlling vascular risk
factors serves to delay onset of AD. In fact, a recent statement by the World Dementia
Council suggested that “Regular physical activity and management of cardiovascular
risk factors (e.g. diabetes, obesity, smoking, and hypertension) are associated with a
reduced risk of cognitive decline and may reduce the risk of dementia” [273,274]. A
recent cross-sectional study concluded that the use of certain medications to treat
vascular disease, especially angiotensin receptor blockers and diuretics, may decrease
Aβ accumulation [275]. In a recent review, Deckers et al (2015) [276] found that the
most common modifiable risk factors for AD development included hypertension,
diabetes, midlife obesity, physical inactivity, hyperlipidemia, and smoking. Simple,
inexpensive interventions involving diet and exercise in midlife could be very useful
tools to prevent CVD, CBVD, and AD. These interventions are currently under
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evaluation by several large prospective clinical trials, including the CAIDE [277] and
the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and
Disability (FINGER – [278]). Nonetheless, preliminary results indicate that the
complex multifactorial nature of AD requires interventions that simultaneously target
multiple risk factors and disease mechanisms during the preclinical stage of the
disease [277,278].The CAIDE screening tool has been developed based on vascular
and metabolic factors shown to increase dementia risk in order to identify individuals
who are at-risk for dementia and who require preventive intervention [45] and this has
recently been developed into a freely-available smartphone application [277].
The validation of sensitive and reliable measures of dementia risk that account for
CVD susceptibility (e.g., CAIDE), paired with lifestyle intervention techniques to
control or reduce these same risk markers, will ultimately lead to a better
understanding of the relationship between these two disease clusters. The exploration
of the dynamic pathogenic relationships between AD and CVD/CBVD has the
potential to lead to a reduction and/or delay in AD incidence. In accordance with
earlier work revealing that interactions between mechanistic, genetic, and lifestyle
factors influence vascular disease, we expect that these multifactorial interventions
targeting common mechanistic and lifestyle factors in AD and CVD/CBVD will
confirm that the adoption of a heart-healthy lifestyle has the potential to contribute to a
future decline in all three disease processes.
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Future Directions
Despite the rapid advancement of medical technology, we are still developing
a suite of reliable and sensitive diagnostic markers to identify individuals at risk for
AD prior to onset of clinical symptoms. This is an area of research that needs to be
urgently addressed in order to enable the study of early interventions to maintain
quality of life in premorbid AD and to reduce the individual and societal burden of the
disease. There are currently several secondary prevention trials aimed at
pharmacologically slowing or reducing the Aβ accumulation that occurs in preclinical
AD, but as of this writing these secondary prevention trials are still in progress and we
do not yet have successful therapies to prevent or slow/reduce disease progression. It
is typically the case that such large prospective studies seek to exclude participants
with significant cardiovascular or cerebrovascular comorbidities. Given the evidence
supporting a substantial overlap of epidemiology, genetics, risk factors, and
mechanistic factors in vascular and AD pathology, we argue that future secondary
prevention trials should focus on a more heterogeneous and phenotypically
representative population.
Aside from clinical trials and recruitment science, there continues to be an
outpouring of literature aimed at untangling the mechanistic relationships between
CVD, CBVD, and AD. Recently, the National Institutes of Health (NIH) launched the
Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M 2OVEAD) Consortium, the primary aim of which is to construct a comprehensive model of
Alzheimer’s disease that more accurately reflects its complex underpinnings, and the
multiple pathways of disease development. The main objectives of this initiative are to
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elucidate the complex mechanisms by which cardiovascular risk factors influence the
development and progression of AD, and to identify new targets for treatment and
prevention. Thus far, the consortium supports five project areas addressing a wide
range of topics, including: the contribution of Alzheimer’s risk genes (APOE E4) to
AD and CVD, the contribution of DM to AD, CVD, and CBVD, the contribution of
hypertension to AD development and progression, identifying metabolic signatures
underlying risk factors for both AD and CVD, and investigating the mechanism of Aβ
accumulation and clearance at the molecular, single-blood vessel, and whole brain
level and the relationship of Aβ accumulation at all three levels in AD and CBVD.
Moving forward, studies such as these that investigate the interaction of vascular
biology with genetic, cardiometabolic, and lifestyle risk factors and AD pathology will
be crucial to the development of therapeutic agents.
There are many questions about the relationships between AD, CBVD, and
CVD that remain unanswered. One important public health question is how these
diseases intersect in the oldest old. The World Health Organization has reported a
world-wide dementia incidence of 47.5 million in 2015, and a projected incidence of
75.6 million in 2030. The largest risk factor for AD, CVD, and CBVD is increasing
age. In the United States, the population of adults aged ≥90 is expected to grow over
six-fold by 2050 [271]. As the average lifespan increases, the social and economic
consequences of AD, CVD, and CBVD are expected to expand accordingly. Due to
difficulties in finding, recruiting, and diagnosing the oldest-old, very little literature
exists examining the relationships between AD, CBVD, and CVD in this population.
Future population-based studies should aim to include this cohort in order to further

38

understand the nature of disease interactions over time, and to identify prevention
targets to reduce cardiovascular risk (i.e. blood pressure, glycemic index, and
cholesterol levels) in these specific populations. More accurate models are required for
assessing prognosis and life expectancy in older adults with AD, CVD, and/or CBVD
in the context of multiple chronic conditions.
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Tables
Table 1. Shared evidence-based treatments for cardiovascular disease (CVD) and
Alzheimer’s disease (AD). Note: Given the breadth of this literature, all cited
references are exemplars published within the past 10 years, and all are empirical
reports.
Specific Medication
Interventions
Diuretics

Angiotensin receptor 1blocker (ARB) or
angiotensin-converting
enzyme (ACE)
inhibitor
β-blockers

Statins

Anti-Inflammatory
Drugs

Insulin Treatment

Specific Behavioral
Interventions
Aerobic Exercise &
Physical Fitness

Healthy Diets (e.g.,
MIND diet)

Clinical Effects in Treatment of
CVD
Thiazide diuretics lead to
lowering of blood pressure
[279,280].
Reduce risk of cardiovascular
events [281,282].

Clinical Effects in Treatment of AD

β-blockers can prevent
cardiovascular events in patients
at increased cardiovascular risk
[283,284].
Reduce risk of cardiovascular
events [285,286].

β-blocker use is associated with a
lowered risk of developing
cognitive impairment in older
adults without dementia [63,65].
Mixed literature, with no
consistent evidence that statins
reduce the incidence of AD or
slow cognitive decline [87,88].
Mixed literature, suggesting that
NSAIDs may confer modest
protective effects [10,11]. Lowdose aspirin is commonly used as
an anti-platelet agent for stroke
prevention.

Mixed literature on use of Nonaspirin anti-Inflammatory drugs
to reduce cardiovascular risk
[287,288]. Low-dose aspirin is
commonly used as an antiplatelet agent for secondary
CVD prevention.
Effective diabetes treatment
confers long-term beneficial
effects on risk of CVD
[289,290].

Long-term protective effects on
risk of cardiovascular disorders
[291,292].

Healthy diets may protect
against CVD [293,294].
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Long-term use of diuretics may be
associated with decreased
incidence of AD [61,62].
ARB and ACE inhibitors may
slow progression of symptoms in
mild-moderate AD [62,64].

Intranasal insulin appears to
improve cognition and modulates
Aβ aggregation in early AD [111,
94].

Aerobic exercise promotes brain
vascularization and may reduce
vascular risk factors as well as to
improve cognitive function
[125,127].
High-fat diets have shown an
increased risk for AD
[112,115]. Conversely, carefully
designed diets have been shown to
confer protective effects [113,114].

Table 2. Domains of shared patient characteristics and pathophysiology between
cardio- and cerebrovascular disease, and Alzheimer’s disease.

Patient Characteristics
Age range
Genetic risk factor
Hypertension/ Hypotension
High Cholesterol
Diabetes Mellitus
Obesity
Smoking
History of depression
Pathogens (e.g., fungal)
Air pollution

AD
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

CVD/CBVD
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Key References numbers
2, 34,35,189
23-33, 264-266
34,35,38,39-44,51-69
36,71-86
34,35,38-44,89-110
111-121
124-137
34,35,39-45,143-154
157-168
169,170
176-179

Pathophysiology
Reduced cerebral blood flow
Aβ deposition
Morphological changes in vasculature
Alterations in BBB permeability
Cholinergic neurodegeneration

AD
Yes
Yes
Yes
Yes
Yes

CVD/CBVD
Yes
No
Yes
Yes
Yes

Key References numbers
182,209-217
184,218-225
49,180,181,226-234
235-247
248-263

Poor physical fitness
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Abstract

To explore early autonomic cardiac changes in pre-clinical AD, we have evaluated
electrocardiologic measures of vagal tone for 63 adults (ages 55-75) at rest, during
cognitive testing, and then again at rest. All subjects had multiple risk factors for AD,
and all completed amyloid PET scans (18F-Florbetapir) to determine amyloid
positivity (Aβ+).
No change in ECG measures were observed for Aβ+ participants under each testing
condition, whereas Aβ- subjects showed an expected increase in vagal tone during the
cognitive stress condition. These findings suggest an early relationship between
cortical Aβ accumulation, a precursor to AD development, and autonomic cardiac
function.

Keywords
Alzheimer’s disease, cardiac, vagal tone, resting sinus arrhythmia, aging, heart rate
variability
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Introduction
A recent review of the complex relationship between Alzheimer’s disease
(AD), cardiovascular disease (CVD), and cerebrovascular disease (CBVD) [1]
highlights the many shared risk factors and pathophysiologic mechanisms across these
diseases and, as a result, the preclinical stages of these diseases may often
concurrently affect the same at-risk population [1]. Clinical studies demonstrate that
even mild cerebrovascular pathology results in reduced cognitive performance in very
early AD [2,3]. Additionally, there is evidence that vascular/cerebrovascular
pathology can accelerate the progression of AD [4,5]. Moreover, the blood-brain
barrier seems to be disrupted early in AD, causing dysfunction in brain perfusion [6]
and reduced cerebral blood flow [7]. It remains unclear just how early in the disease
course the shared pathological relationships between AD, CVD, and CBVD can be
observed. The exploration of the mechanistic relationships between these disease
clusters in a preclinical population is important to better understand the complicated
co-occurrence of these three diseases.
We recently examined the relationship between CNS amyloid beta (Aβ)
burden, and a simple measure of myocardial oxygen consumption: rate pressure
product (RPP), a well-known cardiac workload marker that reflects myocardial stress
based on the number of times that the heart needs to beat per minute in relation to the
arterial blood pressure that it is pumping against. In cognitively normal participants at
high-risk for the development of AD [8]. This work supports a relationship between
elevated neocortical Aβ aggregation and inefficient myocardial oxygen consumption
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in the absence of significant metabolic demands (after accounting for expected effects
of age).
In the current study, we sought to explore if the changes in cardiac workload
that we see in preclinical AD during cognitive testing are due to centrally-mediated
changes in vagal tone measured by vagal ratio and the resting sinus arrhythmia (RSA).
Both of these indices become less reactive and they decrease in amplitude with normal
aging, due to declines in parasympathetic tone [9,10]. The vagal ratio is the ratio
between low and high frequency components of the Heart Rate Variability (HRV) and
the RSA is a measure of the HRV in synchrony with respiration. In this study, rapid
changes in these two indices of vagal tone were measured before, during, and
immediately after the administration of a cognitive stressor, to explore the adaptive
flexibility of parasympathetic autonomic function in response to a mild cognitive
stressor (performance on a hidden maze learning task).
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Methods

Participants: Sixty-three adults aged between 55 and 75 years (mean age =
62.79 years), all at some risk for development of Alzheimer’s disease (AD) based on
the presence of two risk factors for the disease (a first degree family history and
subjective memory complaints), were recruited for a longitudinal study of individuals
with possible preclinical AD [11]. From this larger sample, we identified 15
participants who were categorized as presenting with preclinical stage disease based
on evidence of both 1) elevated neocortical beta-amyloid burden as determined by
PET amyloid imaging [12,13]; and 2) relative cognitive impairments in response to a
challenge with a very low-dose muscarinic anticholinergics [11,14]. Potential
participants were excluded from this study if they presented with diagnoses of either
mild cognitive impairment (MCI) or AD, following NIA-AA diagnostic criteria
[13,15], diabetes, or histories of any neurological or psychiatric disorders. With
respect to cardiovascular risk, four of 15 subjects in the preclinical AD group (26.7%)
and 12 of 48 subjects in the control group (25%) presented with hypercholesterolemia
that was under medication control. Two individuals in the preclinical AD group
(13.3%) and 8 persons in the control group (16.6%) were under treatment for
hypertension. For all subjects, a score on the Mini Mental State Examination (MMSE)
>27 was required for study entry.
With respect to genetic risk for AD, eight of 15 individuals (53%) in the
preclinical AD group (Florbetapir PET SUVr scores ≥1.10) had at least one copy of
the APOE ε4 allele, whereas 20 of 45 individuals (45%) in the control group
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(Florbetapir PET SUVr scores < 1.10) had at least one copy of the APOE ε4 allele.
Hence, roughly half of the subjects in each group presented with this additional risk
factor for AD, but due to small sample sizes we were not able to further evaluate the
specific effect of APOE genetic risk on the relationship between vagal tone and
cognitive performance. Subject demographic information, for both groups, are
provided in Table 1.

Neuroimaging: PET scans were performed at baseline, with 370MBq (10 mCi
+/- 10%) bolus injection of 18F-florbetapir administered intravenously. PET
standardized uptake value (SUV) data were summed and normalized to the whole
cerebellum SUV, resulting in a region-to-cerebellum ratio termed SUV ratio (SUVr).
We defined amyloid positivity (Aβ+) as individuals with elevated ligand binding
(SUVr≥1.1) in the anterior cingulate (ACC). Consistent with Lim et al. (2015) [14],
this specific region of interest was selected because: (1) the young age of participants
enrolled in the study [16,17], and as such, we would not expect widespread neocortical
amyloidosis in this very early preclinical disease stage, (2) the relationship between
the ACC and early changes in cholinergic tone [18,19], and (3) emerging research that
suggests that increased Aβ burden, in the ACC specifically, is related to memory
changes in early AD [20,21]. The SUVr calculation was performed using MIMneuro
software [22]. For all cases, Aβ positivity was confirmed by consensus over-read by
two board-certified radiologists who were also board-certified in Nuclear Medicine
[14].
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Cardiac measures: Electrocardiographic (ECG) measures of resting-sinus
arrhythmia (RSA) and vagal ratio (described above) were recorded by BioPac Systems
[23] for each participant: 1) at rest, sitting quietly in a semi-supine position (120
seconds); 2) during the performance of the Groton Maze Learning Test (GMLT;
approx. 190 seconds); and 3) post-test at rest in a semi-supine position (120 seconds).
Both measures were calculated using the Heart Rate Variability (HRV)
analysis of fixed- width intervals around events, which follows the European Heart
Journal guidelines [24] for the spectral method with the Multi-epoch HRV processing
[25].
RSA is computed using the peak-valley method, which uses both a recorded
ECG signal and a respiration signal. By using respiration information, this analysis
method can provide breath-to-breath analysis that does not require parameter tweaking
for individual subjects [23,26].
The vagal ratio measure accounts for the fact that parasympathetic control via
the vagus nerve is believed to primarily modulate the R-R intervals at a rate of
between 0.15 and 0.4 cycles per second. Frequency based analysis of HRV in
AcqKnowledge computes vagal ratio as the amount of power in the parasympathetic
band normalized to an approximation of the total power in the signal [25].
Cognitive Assessment: All participants completed the Groton Maze Learning
Test (GMLT; http://www.cogstate.com) as a mild cognitive stressor, during the ECG
recording. The GMLT is a computerized hidden spatial maze learning task, developed
by one of the authors (P.J.S.) as a measure of working memory, learning efficiency
and reasoning/problem solving [27]. This GMLT composite score was used to explore
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group differences in performance. All subjects completed a practice trial of the
GMLT, to allow for initial task familiarity; and after a 10-min break, all subjects
repeated the GMLT as a baseline assessment (at which time ECG recordings were
obtained, as described above).
Additionally, all subjects completed a test of verbal episodic memory:
International Shopping List Test (ISLT) [28], the Mini-Mental State Examination
(MMSE) as a measure of general cognitive function, the 15-item Geriatric Depression
Scale and the Depression, Anxiety and Stress Scale (DASS). Subjective memory
impairment was determined using the Memory Complaint Questionnaire (MAC-Q).
All measures were performed by trained staff supervised by a licensed clinical
neuropsychologist.

Statistical Treatment of Data: Generalized estimating equations (GEEs) were
used to compare within-subject changes in vagal ratio and RSA across the three time
points (rest à cognitive task à rest) between preclinical AD subjects (N=15) and the
control subjects (N=48). GEEs are generalized linear models wherein the withinsubjects (or other) nesting is accounted for in the residual error of the model (R-side),
as contrasted with constructing random effects separate from the residual (G-side as in
random, mixed, or hierarchical models) [29]. In our case, a compound symmetry
variance-covariance matrix was used across testing phases, which assumes a common
variance for each phase as well as a common covariance between all phases. Despite
best intentions and approach, there can be non-obvious imprecision in these
specification and so classical sandwich estimation [30] was used to adjust for any
misspecification in this structure by subsequently adjusting the variances and
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covariances in the structure based on the actual distribution of the data (inverse of the
empirical variance “sandwiched” between model variance(s)). The Shaffer step-down
adjustment was used to maintain alpha at 0.05 across all comparisons within each
model. Figures 2 and 3 were designed to simultaneously illustrate between- and
within-participant variation.
This study was approved by and complied with the regulations of Rhode Island
Hospital’s Institutional Review Board, and all participants provided written informed
consent.
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Results

There were no statistically significant differences between the two groups for
any demographic or clinical outcome, with the exception of the expected elevation in
cortical amyloid aggregation as demonstrated on florbetapir PET scan (Table 1).
There were also no between-groups differences in at-rest vagal ratio or RSA, with
respect to main effects for APOE ε4 carrier status, presence of hypercholesterolemia
and hypertension (p > .05 for all analyses).
----------------------------------------------------Insert Table 1 About Here
-----------------------------------------------------

With respect to performance on the GMLT, no between-groups differences on
the composite score [14], were found between those with Aβ+ PET scans vs. those in
the Aβ- healthy control group.
----------------------------------------------------Insert Figure 1 About Here
-----------------------------------------------------

However, subjects in the healthy control group (those with Aβ- PET scans)
showed an increase in vagal ratio during the cognitive task condition, relative to either
of the two at-rest conditions (Pre-GMLT: p=0.0061; adj. p=0.0304; Post-GMLT:
p<.0001; adj. p=0.0007), with post-GMLT vagal ratio not differing significantly from
pre-GMLT levels (p=0.2283; adj. p=0.9185). In contrast, the preclinical AD (Aβ+)
group did not consistently show any change in vagal ratio at any point during testing
(pre- vs. GMLT p=0.1837, GMLT vs. post- p=0.2221, post- vs. pre-GMLT p=0.7883;
adj. p =0.9985 for all). Further, the increased vagal ratio during the cognitive stress
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condition (p=0.0099; adj. p=0.0304) and subsequent decreases (p=0.0013; adj.
p=0.0007) for the Aβ- group differed significantly from the Aβ+ group.
----------------------------------------------------Insert Figure 2 About Here
-----------------------------------------------------

Similarly, to vagal ratio, the Aβ- subjects showed a significant increase in RSA
during the cognitive task condition, relative to either of the two at-rest conditions (PreGMLT: p<.0001; adj. p<.0001; Post-GMLT: p=<.0001; adj. p=0.0003), with postGMLT RSA not differing significantly from pre-GMLT levels (p=0.2471; adj. p=1.0).
As with the vagal ratio measure, those in the Aβ+ group did not consistently show any
change in RSA at any point during testing (pre- vs. GMLT p=0.6321, GMLT vs. postp=0.7719, post- vs. pre-GMLT p=0.8510; adj. p =1.0 for all). Further, the increased
RSA scores during the cognitive stress condition (p=0.0021; adj. p=0.0104) were
significantly larger for the Aβ- group compared to the Aβ+ group. The subsequent
decrease in RSA for the Aβ+ group after the cognitive stress were significantly greater
than for the Aβ- group prior to adjustment, but not after multiplicity adjustment
(p=0.0304; adj. p=0.0913).
----------------------------------------------------Insert Figure 3 About Here
-----------------------------------------------------
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Discussion

Participants in this preclinical AD (Aβ+) group demonstrated statistically
significant attenuation in the reactivity of two separate measures (vagal ratio and
RSA) of parasympathetic response to a mild cognitive stress condition. Not only was
the magnitude of their response to the cognitive stressor less than those without
elevated neocortical Aβ, but no significant differences found for these measures,
within the Aβ+ group, across any of the three ECG time points. In order to further
explore the relationship between neocortical Aβ aggregation and inefficient
myocardial oxygen consumption in the absence of significant metabolic demands [8],
it is essential to rely on metrics that accurately reflect the autonomic processes that
control cardiac function. Cardiac autonomic dysfunction is prevalent among
individuals with AD, and this generally reflects a decrease in parasympathetic activity
[31,32]. It has been previously shown that individuals with MCI demonstrate
significant parasympathetic deficits [33]. The parasympathetic nervous system (PNS)
influences heart rate by the release of acetylcholine (ACh) via the vagus nerve, which
causes the heart rate activity to slowdown. This reduction in PNS activity is often
referred to as vagal withdrawal, and is indicative of impaired autonomic function [34].
The ratio between low and high frequency components of the HRV (the LF/HF
ratio, or vagal ratio) has long been relied on as a measure of sympatho-vagal balance
[35,36,37]. Healthy individuals under mental stress while completing a cognitive task
showed a reduced HF HRV component compared to a control group who were
monitored whilst awake and at rest [38,39]. The clinical reliability of this vagal ratio
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as marker of autonomic activity has been nonetheless controversial [40,41]. Therefore,
we have chosen to supplement this measure of autonomic cardiac function in
preclinical AD by computing the respiratory sinus arrhythmia (RSA), which considers
the variation in heart rate during the breathing cycle and is commonly relied on as a
measure of parasympathetic nervous system activity. Typically, both vagal ratio and
RSA decrease with normal aging due to decline in parasympathetic tone [9,10].
Disruption of cholinergic neurotransmission with low-dose scopolamine has
been previously shown to exacerbate subtle cognitive deficits that are otherwise not
(yet) detectable for subjects in the Aβ+ group [14], whereas standard baseline testing
with the GMLT does not reveal any group differences. We believe that the subjects
enrolled in the Aβ+ group, for this study, are in the preclinical stage of the disease and
that it might be too early to observe clear impairments in learning efficiency and
working memory/executive function unless such defects are unmasked by
intentionally down-regulating cholinergic tone [14].
Participants in this Aβ+ group, however, did not consistently show changes in
vagal ratio or RSA at any point during the experiment, failing to demonstrate the
expected response to modest stress elicited during cognitive task performance. Both
measures were expected to show modest increases, reflecting heightened autonomic
arousal, during completion of a neuropsychological test, even after adjusting for age
effects [42]. Enhanced vagal ratio is characterized by greater vagal reactivity and
faster vagal recovery from psychological stressors, and it has been linked with greater
ANS flexibility and an improved response selection in the face of stress [43,44] and
return to homeostasis [45]. Conversely, in a study of healthy male sailors who
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completed a fitness training program, those with higher vagal ratio scores
demonstrated improved performance on measures of working memory, reaction time
and attentional controls [46]. In our study, the Aβ- group demonstrated an expected
increase in vagal ratio in response to the cognitive stressor, whereas the Aβ+ group
demonstrated no change in vagal ratio across all three testing conditions.
The same pattern of results was observed for the related RSA measure, with
participants in the Aβ- group showing an expected increase in RSA during GMLT
performance. RSA is a composite of integrated respiratory and cardiovascular
responses [47] that are responsive not only to metabolic demands but also to levels of
alertness and, in humans at least, different types of emotion, mental activity and
arousal metabolism [48]. Typically, expression of RSA decreases with age [49];
however, adults in excellent cardiovascular health, such as athletes, are likely to have
a higher RSA [50]. Higher RSA is also usually associated with fewer errors in a
complex memory task, on measures of attentional control and response selection and
on cognitive function tasks that are associated with the integrity of the ACC [51].
Aβ+ participants showed decreased RSA compared to Aβ- during the cognitive test,
and this pattern was present in participants with cognition impairments or with
diabetes and cardiovascular disease [10].
Cardiac autonomic dysfunction is prevalent among individuals with AD, as
reflected by exacerbated sympathetic nervous activity and decreased parasympathetic
nervous activity [31,52,53,54]. The results of the current study suggest that for
individuals identified as falling within the preclinical stage of AD (our Aβ+ group),
there is a muted response on two related indices of phasic vagal cardiac control, RSA
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and vagal ratio, when presented with a modest cognitive stressor. Both RSA and vagal
ratio are directly modulated by both muscarinic and nicotinic cholinergic autonomic
neurotransmission, and the earliest stages of AD are marked, in part, by altered
function of the basal forebrain cholinergic system, with eventual degenerative changes
including neuronal loss [54]. We have recently reported that a down-regulation of
central cholinergic neurotransmission appears to be one of the earliest
neuropathological changes in preclinical AD [14] and we have also found that
individuals with evidence of both decreased central cholinergic tone and amyloid
aggregation within the ACC region show evidence of increased resting cardiac
workload [8]. The aggregation of Aβ plaques in the neocortex, within this specific
region of interest that is part of the central cholinergic system, appears to be directly
associated with higher cognitive impairment as well as myocardial oxygen
consumption [8]. These results add to a growing body of literature that suggests a
direct link between Aβ aggregation, basal forebrain cholinergic damage, and impaired
cardiovascular function, even in the preclinical stage of Alzheimer’s disease [1].
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Tables
Table 1. Demographic Characteristics

Main Outcome

Sex
APOE
Hypertension
Hypercholesterolemia

No. of female
Number of Ɛ4
carriers
Number of
participants
Number of
participants

Full sample
(n = 63)
N (%)
39 (61.9%)
29 (46%)

Preclinical
AD
(n = 15)
N (%)
11 (73.3%)
8 (53.3%)

Healthy
Controls
(n = 48)
N (%)
28 (58.3%)
21(43.8%)

p
.296
.516

10 (15.9%)

2 (13.3%)

8 (16.6%)

.758

16 (25.4%)

4 (26.7%)

12 (25%)

.897

Mean (SD)

Mean (SD)

Mean (SD)

p

Cohen’s d

62.44 (5.04)

.349

0.28

17.14 (2.55)

.689

0.12

0.95 (0.08)

.000

2.95

Age

No. of years

62.79 (5.35)

Education

No. of years

17.21 (2.77)

Florbetapir PET
SUVr (ACC region
of interest)
GDS
DASS Depression
Subscale

Standardized
Uptake Value
ratio
Total Score
Total
Depression
Subscale Score
Total Anxiety
Subscale Score
Total Stress
Subscale Score
Body Mass
Index
Total Score

1.04 (0.19)

63.93
(6.31)
17.47
(3.46)
1.30 (0.20)

1.86 (2.16)
3.56 (6.70)

1.60 (1.45)
2.60 (2.59)

1.94 (2.35)
3.87 (7.56)

.602
.526

-0.16
-0.19

2.73 (4.53)

2.40 (3.58)

2.83 (4.83)

.752

-0.09

6.73 (6.77)

6.67 (4.55)

6.74 (7.38)

.969

-0.01

26.69 (5.50)

26.07 (4.41)

.113

0.48

29.08 (0.99)

.624

-0.15

Total words
recalled

25.59 (4.22)

28.66
(7.95)
28.93
(1.16)
24.73
(4.46)

25.85 (4.16)

.374

-0.26

DASS Anxiety
Subscale
DASS Stress
Subscale
Body Mass Index
MMSE
ISLT Total Recall

29.05 (1.02)

*Note: SUVr = standardized uptake value ratio; ACC = Anterior Cingulate Cortex; GDS =
Geriatric Depression Scale; DASS = Depression, Anxiety, and Stress Scale; MMSE = Mini
Mental State Examination; ISLT = International Shopping List Test; bolded value is
significant at the p<.001 level
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Figures Legends

Figure 1. GMTL composite z-scores for participants with low (left) versus high
(right) for Aβ aggregation in the anterior cingulate region of interest (PET amyloid
imaging) (p > 0.05).
Figure 2. Plots of vagal ratio in patients testing negative (blue, left) and positive
(red, right) for Aβ (ACC) as a function of pre-, during, and post-GMLT testing.
Least squares means (large circles) and 95% confidence intervals were adjusted for
age. Small circles indicate the raw individual patient values for each phase of
testing in order to convey the variability in values between patients. Light gray
lines illustrate the individual changes relative to pre-GMLT testing (normalized to
pre-GMLT by subtraction) in order to convey the consistency of within-subject
changes. Aβ- group showed an increase in vagal ratio during the cognitive task
condition, relative to either of the two at-rest conditions (Pre-GMLT: p=0.0061;
adj. p=0.0304; Post-GMLT: p<.0001; adj. p=0.0007), with post-GMLT vagal ratio
not differing significantly from pre-GMLT levels (p=0.2283; adj. p=0.9185). Aβ+
group did not consistently show any change in vagal ratio at any point during
testing (pre- vs. GMLT p=0.1837, GMLT vs. post- p=0.2221, post- vs. pre-GMLT
p=0.7883; adj. p =0.9985 for all). Further, the increased vagal ratio during the
cognitive stress condition (p=0.0099; adj. p=0.0304) and subsequent decreases
(p=0.0013; adj. p=0.0007) for the Aβ- group differed significantly from the Aβ+
group.
Figure 3. Plots of RSA in participants testing negative (blue, left) and positive (red,
right) for Aβ (ACC) as a function of pre-, during, and post-GMLT testing. Least
squares means (large circles) and 95% confidence intervals were adjusted for age.
Small circles indicate the raw individual patient values for each phase of testing in
order to convey the variability in values between patients. Light gray lines
illustrate the individual changes relative to pre-GMLT testing (normalized to preGMLT by subtraction) in order to convey the consistency of within-subject
changes. Aβ- subjects showed a significant increase in RSA during the cognitive
task condition, relative to either of the two at-rest conditions (Pre-GMLT: p<.0001;
adj. p<.0001; Post-GMLT: p=<.0001; adj. p=0.0003), with post-GMLT RSA not
differing significantly from pre-GMLT levels (p=0.2471; adj. p=1.0). As with the
vagal ratio measure, those in the Aβ+ group did not consistently show any change
in RSA at any point during testing (pre- vs. GMLT p=0.6321, GMLT vs. postp=0.7719, post- vs. pre-GMLT p=0.8510; adj. p =1.0 for all). Further, the
increased RSA scores during the cognitive stress condition (p=0.0021; adj.
p=0.0104) were significantly larger for the Aβ- group compared to the Aβ+ group.
The subsequent decrease in RSA for the Aβ+ group after the cognitive stress were
significantly greater than for the Aβ- group prior to adjustment, but not after
multiplicity adjustment (p=0.0304; adj. p=0.0913).
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Structured Abstract

Introduction: We conducted a 27-month longitudinal study of mid-life adults with
preclinical Alzheimer’s disease (AD), using Spectral domain Optical Coherence
Tomography (SD-OCT) to compare changes in volume and thickness in all retinal
neuronal layers to those of age-matched healthy control subjects.
Methods: Fifty-six older adults (mean age = 65.36 years) with multiple risk
factors for AD completed SD-OCT retinal imaging and cognitive testing at
baseline. Twenty-seven months later they completed the same exams as well as an
18
F-Florbetapir PET imaging study.
Results: Compared to healthy control subjects, those in the preclinical stage of AD
showed a significant decrease in macular retinal nerve fibre layer (mRNFL)
volume, over a 27-month follow-up interval period, as well as a decrease in outer
nuclear layer (ONL) and inner plexiform layer (IPL) volumes and thickness in the
inferior quadrant. However, only the mRNFL volume was linearly related to
neocortical PET amyloid SUVr after controlling for any main effects of age
(R2=0.103; ρ = 0.017). Furthermore, the magnitude of mRNFL volume reduction
was significantly correlated with performance on a task of participants’ abilities to
efficiently integrate visual and auditory speech information (McGurk effect).
Discussion: We observed a decrease in mRNFL, ONL and IPL volumes, in
preclinical AD relative to controls. Moreover, the largely myelinated axonal loss in
the RNFL is related to increased neocortical Aβ accumulation after controlling for
age. Volume loss in the RNFL, during the preclinical stage, is not related to
performance on measures of episodic memory or problem solving. However, this
retinal change does appear to be modestly related to relative decrements in
performance on a measure of audiovisual integration efficiency that has been
recently advanced as a possible early cognitive marker of mild cognitive
impairment.

Keywords
Pre-clinical, Alzheimer’s disease, retinal, cognition, RNFL, OCT, Optical
Coherence Tomography, McGurk Effect, Amyloid
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Research in Context

Systematic Review
We reviewed 15+ years of literature on the relationship between the morphology
of retinal neuronal layers and Alzheimer’s disease (AD), and the evidence of
disease-related retinal change over the progression of AD. This literature is mixed,
with inconsistent findings, and it consists mostly of cross-sectional studies in
patients with symptomatic disease. We were unable to identify prior publications
that have sought to explore within-subjects longitudinal change in retinal
morphology during the preclinical stage of AD for all retinal neuronal layers.
Interpretation
After controlling for expected effects of normal aging, we observed a decrease in
the macular region of the RNFL (mRNFL) that is moderately correlated with PET
imaging evidence of amyloid aggregation. Volume loss in the mRNFL, during the
preclinical stage, is not related to performance on measures of episodic memory or
problem solving, but is modestly related to relative decrements in performance on
a measure of visual-auditory integration of new information. This may be a first
report of neuronal retinal layer volumetric changes in a within-subjects,
prospective and longitudinal study of preclinical AD.
Future directions
Larger populations of participants, across the entire disease severity spectrum
(from healthy controls to mild AD), should be followed for an even longer time
interval in order to better model the natural history of retinal anatomic changes
over the entire course of disease progression. Additional imaging methods could
improve our understanding of the mechanisms of disease-related retinal change,
such as OCT Angiography and scanning polarimetry.
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Background

The formation of the eye begins in the third week of human embryologic
development, with the retina being a crucial component of the ocular globe and the
central nervous system (CNS). The retina is derived from pluripotent
neuroectodermal cells that migrate from the diencephalic invagination of the neural
tube [1], and so it is structurally, physiologically, and functionally brain tissue —
with the retina sometimes described as a “protrusion” from the brain. As is the
case throughout the neocortex, the retina consists of discrete neuronal cell layers,
with multiple types of neurons and neurotransmitter systems, glial cells and
microvasculature. Unlike the rest of the CNS, however, the retinal neuronal cell
layers can be non-invasively visualized through high-resolution optical methods
such as spectral domain optical coherence tomography (SD-OCT) [2].
A recent review [3] cites the wide variety of retinal biomarkers that have been
explored in patients with Alzheimer’s disease (AD), ranging from retinal
anatomical and vascular markers, to curcumin binding studies [4], retinal oxymetry
and electroretinogram (ERG) studies. Clinically, it is reasonable to suspect the
presence of early ocular involvement in AD because visual system changes such as
decreased vision, abnormal pupillary reaction, visual field changes, motion
detection abnormalities, impaired color vision, and decreased contrast sensitivity
have been identified in mild-to-moderate AD [3,5].
SD-OCT allows for the precise segmentation and measurement of the
retinal cell layers, thereby promoting exploration of neuronal changes that might
be directly related to specific neurodegenerative diseases. Over the past two
decades there have been over 70 peer-reviewed publications exploring retinal
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optical coherence tomography (OCT) correlates of Alzheimer’s disease, in
humans, non-human primates, and other animal models of AD disease. With
respect to humans, most prior reports have consisted of cross-sectional studies
comparing groups of AD patients to groups of seemingly “healthy controls”.
When compared with healthy age-matched controls, patients with AD have
reduced numbers of ganglion cell axons, and are three times more likely to have an
increased optic nerve cup-to-disc ratio, a potential consequence of ganglion cell
and nerve fiber loss [6]. Such reports have confirmed an earlier report of
substantial loss of ganglion cells in AD patients, based on histopathology of
autopsy materials [7]. Further, peripapillary retinal nerve fiber layer (pRNFL)
thickness has been found to be significantly thinner, suggesting the presence of
optic atrophy in patients with mild cognitive impairment (MCI) and mild-tomoderate AD when compared with age-matched controls [8]. Reduction of
macular RNFL volume (mRNFL) also has been identified in AD [9]. The loss of
RNFL tissue in the retina may constitute an early biomarker of AD. If so, a
reduction in RNFL thickness or volume may be observed prior to widespread
damage to the mesiotemporal CNS memory system that is characteristic of AD
[10,11,12].
With respect to the RNFL we have surveyed all available literature,
including those studies relying on other imaging approaches, such as 2D fundus
photography and histological analyses, and we have found variable reports of
decreased RNFL and/or ganglion cell layer (GCL) thicknesses in AD and MCI. A
search on Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/) was performed (25
August, 2017) to find all published articles, using the search terms “Alzheimer’s”
and “retinal layer”. This search led to 134 papers identified and, of these, only 34
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papers consisted of human studies that compare retinal layer morphology changes
in Alzheimer’s patients to healthy individuals (see Table 1).
Nearly all of these 34 publications resulted from cross-sectional studies
based on comparisons of cases to putatively ‘healthy controls’. Most often the
healthy controls had no biomarker confirmation to indicate that they did not fall
within the preclinical stage of AD. One study did search for thickness differences
in all 10 retinal layers [20], with the remaining 33 studies concentrating on
measurement differences for the mRNFL, pRNFL and the GCL. Of note, the GCL
was only once reported as a single layer [20], being most often considered in
conjunction with an adjacent cell layer, either as the ganglion cell – inner
plexiform layer complex (GC-IPL complex) or as the retinal nerve fiber layer –
GCL complex (RGCL or GCC).
From the 33 papers seeking to compare group differences for the RNFL, 29
found RNFL thinning in AD compared with age-matched controls (see Table 1).
Only seven of these 29 published reports appear to have accounted for participant
age as a statistical co-variate in their analyses. This is important because there is
normal age-related thinning of the RNFL and other retinal layers [44]. Of these
seven publications that did account for effects of aging, one determined that the
observed thinning was due primarily to the main effect of aging rather than disease
burden [26]; one study found RNFL thinning in MCI but not in AD [30]; two
studies reported RNFL thinning solely in one or two specific quadrants [13, 32];
and three studies reported robust disease-burden after accounting for age [15, 17,
18]. Only two of the 33 reviewed studies reported within- subjects longitudinal
results (both in symptomatic AD patients vs. controls), and they both reported
increased RNFL thinning compared with controls [18, 27].
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Alzheimer’s disease-related amyloid-beta (Aβ) plaques can start to
accumulate abnormally in the brain up to 20 years before symptom onset, and this
stage is classified as pre-clinical AD [45,46]. Only two of the studies reviewed
above, both relying solely on cross-sectional data, recruited individuals in the preclinical stage of the disease. One from the same larger study that we draw from in
the current report [16], found a thicker inner plexiform layer (IPL) in preclinical
AD compared with healthy controls. Another study [14] found no difference in the
RNFL thickness between AD, preclinical AD and healthy controls. Golzan and
colleagues reported a significant difference in the RGCL thickness across the three
groups, and yet they found no association between retinal structural measurements
and PET Aβ binding in the neocortex. Aside from these two cross-sectional studies
of preclinical AD [14, 16], none of the other published reports compared PET
imaging evidence of neocortical amyloidosis with the retinal OCT measurements
for this earliest stage of the disease.

-------------------------------------------Insert Table 1 About Here
--------------------------------------------

In this current report, we followed the same cohort of subjects at high-risk
for preclinical AD over 27 months to explore changes in all retinal neuronal layers
and we relate these findings to PET imaging evidence of cortical amyloid
aggregation in the same participants.
In our current study, we compared morphological changes in retina with
cognitive performance. Previous studies examining this relationship have relied on
the Mini-Mental State Exam (MMSE) as a screening measure of general cognitive
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function, and these studies have led to conflicting results. Some studies have found
no relationship between RNFL thinning and MMSE in AD [41, 47] and MCI [39],
while one study found a correlation between RNFL thickness and MMSE scores in
MCI [29]. Another study reported a correlation between macular volume thinning
(whole retina) and MMSE scores in patients with AD [9]. For individuals in the
pre-clinical stage of disease severity, the MMSE would be a poor choice as a
cognitive marker, due to several psychometric limitations for this test [48]. With
respect to the MCI stage of disease severity, two prior investigators have reported
surprisingly inverse relationships between performance on measures of verbal
episodic memory and RNFL thickness [49, 50]. Importantly, both of these studies
reported cross-sectional data, and it is unclear as to whether this inverse
relationship (that is, relatively enhanced performance on verbal episodic memory
tests associated with relatively diminished RNFL thicknesses) would persist if
participants were followed longitudinally and as the disease progresses.
Our intent was to explore this very question, that of the relationship
between cognitive functioning and evidence of morphologic change in the retina,
over the course of several years, and within the very early, pre-clinical stage of the
disease. Based on prior literature in this specific patient population, we chose the
Groton Maze Learning Test (GMLT) as a measure of learning efficiency, problem
solving and working memory [51,52], and the International Shopping List Test
(ISLT) to measure verbal episodic memory [53, 54]. Finally, we administered an
audiovisual McGurk task, a speech processing paradigm that relies on the integrity
of white matter tracts that underlie corticocortical connectivity, as prior work has
shown disruption of functional integration for posterior sensory regions in AD [55,
56]. Because alterations in white matter integrity may occur in early stages of the
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disease [57, 58, 59], similar early changes in the RNFL - which is comprised
mostly of myelinated axons from the cell bodies in the GCL - might be directly
related to the loss of white matter tracts in the cortex, and hence correlate with
performance on this cognitive task that specifically assesses corticocortical
connectivity and has recently been advanced as a potential biomarker of early stage
AD pathology [60].

Methods
2.1. Participants
A total of Fifty-six adults aged between age 55 and 75 years (mean age =
65.36 years old) with two well-established risk factors for AD, namely, a selfreported first-degree family history of the disease and self-identification of
subjective memory concerns, were recruited using a selection process described
previously [61]. All participants underwent a detailed medical screening
interview. Exclusion criteria included a diagnosis of MCI or AD following the
National Institute on Aging - Alzheimer’s Association (NIA-AA) diagnostic
criteria [45, 62], history of neurological or psychiatric disorder, any significant
systemic illness or unstable medical condition (e.g., active cardiovascular disease),
and current use of any medications known to affect cognition (e.g., use of sedative
narcotics). Subjects with histories of cataract surgery, corneal (LASIK) surgery,
AMD, or subjects with known ophthalmic pathology were excluded. Inclusion
criteria included having an MMSE score of > 27 and performance within normal
limits on a battery of cognitive tests described previously (listed in Table 2)
[63,64]. Since RNFL thinning is a characteristic of glaucoma, subjects with
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glaucoma were excluded. Participants were also excluded if they had a history of
optic neuritis, intraocular surgery apart from cataract extraction, or a history of
visual loss apart from refractive error as these conditions may affect the RNFL
thickness [65, 66, 67]. Additionally, upon examining the OCTs, we excluded any
eye OCT that had evidence of epiretinal membrane [68].
-------------------------------------------Insert Table 2 About Here
--------------------------------------------

All participants live independently, most were engaged in full-time or part
time employment, and many were caretakers for a parent with AD. The amount of
neocortical beta-amyloid protein aggregation (Aβ) and apolipoprotein E (APOE)
genotype were unknown at the time of assessment and were not used to determine
enrollment. Although Aβ status and APOE genotyping were conducted as a part of
the study protocol, researchers remained blinded to these results throughout
testing.
From this larger sample, we identified 15 participants who were
categorized as presenting with preclinical stage disease based on evidence of both
1) elevated neocortical beta-amyloid burden as determined by PET amyloid
imaging [45,46]; and 2) relative cognitive impairments in response to a challenge
with a very low-dose muscarinic anticholinergics [59, 63].
The study was approved by and complied with the regulations of Rhode
Island Hospital’s Institutional Review Board, and all participants provided written
informed consent in accordance with the Declaration of Helsinki. The study
complied with (HIPAA) regulations.

2.2. Aβ PET imaging
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To assess neocortical amyloid burden, all participants had an Aβ PET scan
at baseline and another at 27-month visit. A 370MBq (10 mCi 1/2 10%) bolus
injection of 18F-florbetapir was administered intravenously. Approximately 50
minutes’ post-injection, a 20-minute PET scan was performed with head CT scan
for attenuation correction purposes. Images were obtained using a 128X128 matrix
and reconstructed using iterative or row action maximization likelihood
algorithms. PET standardized uptake value (SUV) data were summed and
normalized to the whole cerebellum SUV, resulting in a region-to-cerebellum ratio
termed SUV ratio (SUVr).
An SUVr threshold of 1.1 or greater was used to discriminate between Aβ+
and Aβ-. These SUVr calculations were performed using the MIMneuro software,
with a normative database of 74 healthy normal individuals (48 males, 26 females),
aged between the ages of 18–50 years, who all had negative amyloid scans on
visual assessment [69]. For all cases, Aβ positivity was confirmed by consensus
over-read by two board-certified radiologists who were also board certified in
nuclear medicine.

2.3. SD-OCT imaging
Participants were administered two drops of tropicamide (Mydriacyl 1%)
per eye for pupil dilation before OCT imaging. The Heidelberg SPECTRALIS SDOCT was used to acquire retinal OCT scans of the optic nerve head and the macula
for the right and left eyes of all participants at baseline and 27 months. Heidelberg
SPECTRALIS has automatic segmentation and quantification of retinal layers,
uses the eye-tracking image alignment for repeated measures (TruTrack;
Heidelberg Engineering, Inc). Outcome measures for the SD-OCT imaging,
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following the Anatomic Positioning System (APS) protocol sequences, included
pRNFL, mRNFL, GCL, inner plexiform layer (IPL), inner nuclear layer (INL),
outer plexiform layer (OPL) and outer nuclear layer (ONL). For each individual
participant, the volume and thickness of all retinal neuronal layers were measured
and averaged for both eyes.
The mean macular thickness of each retinal layer was measured at 4 sectors
(superior, inferior, nasal, and temporal) leading to a macular volume for each
retinal layer (see Fig.1). For the pRNFL, the mean thickness also was calculated in
4 sectors (superior, inferior, nasal, and temporal) centered in the optic nerve and
the thickness of all areas were averaged to result in the average thickness.
-------------------------------------------Insert Figure 1 About Here
--------------------------------------------

The volumes for all layers were obtained separately, across the entire
macular region extending 3.45 mm from the center of the fovea. Mean volumes
(mm3) for reach layer and thickness (μm) for each quadrant (right and left eyes
averaged) were computed for both the baseline and the 27-month time points. The
difference between these two exam time points was obtained for each subject and
for each layer. Multicolor imaging, which uses individual laser wavelenghts [70]
to characterize anatomic and pathologic detail at different retinal depths, served to
identify and exclude individuals with background diabetic retinopathy and retinal
microbleeds within the region of interest.

2.4. Cognitive Assessment
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The Groton Maze Learning Test (GMLT; http://www.cogstate.com) is a
computer administered hidden maze test, designed by one of the authors (P.J.S.) to
measure spatial working memory and problem-solving functions [71]. The GMLT
has been described previously both in terms of performance within the context of
studies with healthy elderly adults [51, 72,73], as well as in MCI [74].
Additionally, all subjects completed the International Shopping List Test
(ISLT; www.cogstate.com) as a measure of verbal episodic memory [75], the
MMSE as a measure of general cognitive function, and the Memory Complaint
Questionnaire (MAC-Q) [76] as a measure of subjective memory complaints.
As noted above, we also administered an audiovisual McGurk Task that has
recently been described as a potential new marker of early-stage AD [60]. The
McGurk effect is a compelling misperception in which discrepant visual and
auditory speech information presented simultaneously results in the listener
hearing a fused audiovisual speech sound, rather than the veridical auditory sound
(e.g., /ba/ auditory + /ga/ visual is heard as /da/ rather than /ba/) [77]. The integrity
and efficiency of the audiovisual integration process can be measured by
comparing accuracy and response times to identify the auditory information under
Congruent (matching audio and visual components) and Incongruent (conflicting
audio and visual components) conditions. For the purpose of this study, we
focused on a measure of integration efficiency, defined as the proportional increase
in response time from Congruent to Incongruent conditions for the weaker
McGurk stimulus in this task. This stimulus condition was particularly sensitive at
discriminating patients diagnosed with amnestic mild cognitive impairment (MCI)
from healthy elderly [60]. Higher efficiency scores reflect greater sensitivity to
binding strength.
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All cognitive measures were performed by trained staff supervised by a
licensed clinical neuropsychologist.

2.5. Statistical Methods
For the demographic variables, t-tests were performed for each variable
between the preclinical AD and healthy control groups. For the layers RNFL
(macular and peripapillary regions), GCL, ONL, outer plexiform layer, inner
nuclear layer and IPL paired 1-sided significance level of 0.05 t-tests were
performed, and the effects sizes for each comparison were computed with the
Cohen’s d statistic. For each layer, the differences between baseline and 27-month
measurements, and between Aβ+ and Aβ- subjects for the total volume, and the
thickness of the average and the quadrants (N3.45, T3.45, S3.45, I3.45) were
computed. Linear regression models were performed with neocortical PET
imaging SUVr entered as a response variable, and retinal layer measures as the
explanatory variables, and covarying for effects of normal aging. Although age
was not significantly different between groups, it is a key predictor of volumetric
loss over time in the macula. In order to assess whether a correlation exists
between retinal layer thickness and any of the cognitive tests, linear regression
analysis (Pearson's test) was adopted, a p value less than 0.05 was considered
significant, and the magnitude of differences was quantified using Cohen’s d.

Results
3.1. Sample Demographics
Of the 56 participants enrolled, 35 were female and 11 of them were amyloid
positive on PET imaging. There were no significant differences between Aβ+ and
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Aβ- groups with respect to sex (p=0.311). Likewise, there were no group
differences in the proportion of individuals with the APOE Ɛ4 genetic risk marker
for AD. The mean age for the total sample was 65.36 years old and this sample
had an average of 17.31 years of education. All relevant demographic information,
for both groups, is provided in Table 2. There were no group differences with
respect to body mass index, subjective memory complaints, cognitive performance
at baseline exam (on any of the tests described above). By definition, both groups
significantly differed with respect to neocortical amyloid aggregation as measured
via PET imaging (p = 0.000).
With respect to genetic risk for AD, eight of 15 individuals (53%) in the
preclinical AD group (Florbetapir PET SUVr scores ≥1.10) had at least one copy
of the APOE ε4 allele, whereas 20 of 45 individuals (45%) in the control group
(Florbetapir PET SUVr scores < 1.10) had at least one copy of the APOE ε4 allele.
Hence, roughly half of the subjects in each group presented with this additional
risk factor for AD, but due to small sample sizes we were not able to further
evaluate the specific effect of APOE genetic risk on retinal layers measurements.
Subject demographic information, for both groups, is provided in Table 2.

3.2. Retinal Layer Measurements
At baseline exam, no group differences were found with respect to either the
thicknesses of any macular quadrant for any neuronal layer, nor were there any
group differences observed with respect to total volumes for each layer in the same
region (Table 3).
-------------------------------------------Insert Table 3 About Here
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-------------------------------------------Change over the 27-month follow-up period, for each of these measures,

was calculated by subtracting the volumes (mm3) and thickness (μm) obtained at
the baseline visit from the same measurements obtained at the 27-month visit. As
shown in Table 4, a significant group difference was found for the mRNFL
(p=0.050), ONL (p=0.026) and IPL volumes (p=0.020). In all cases, the preclinical AD group showed a larger reduction in volume over this time period,
compared to the healthy control group, and in all cases these group differences
were of a moderate effect size. The only significant changes observed in thickness
after controlling for effects of age were in the inferior quadrant of the ONL (0.026)
and IPL (p=0.028), with a larger reduction in the preclinical group, and in the
temporal quadrant of the OPL (0.040), with a larger increase in the preclinical
group compared to the control.
Considering each subject group separately, the change from baseline to 27
months in the total volume (mm3) of the mRNFL was significantly decreased for
the pre-clinical AD group (-0.032±0.003, p=0.002) as well as for the healthy
control group (-0.0190±0.003, p=0.03). With respect to the pRNFL, although we
found an overall non-significant difference in the magnitude of the thinning
between the two groups, over the 27-month period, we observed substantially
greater ranges of variance of measurements for both groups, as reflected by
markedly larger standard deviations (SD) of measurement (Table 3). This region
of the pRNFL is thought to have greater within-subject and between-subject
variability because it contains a multitude of larger diameter blood vessels,
particularly with respect to vascular innervation within the regions of the superior
and inferior arcuate bundles, individual differences in optic canal sizes, the
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presence or absence of space-occupying nerve head drusen, and other individual
differences in this region [78].

3.3. Retinal Layer Change in Relation to Neocortical Amyloid Aggregation
A multivariate linear regression model, controlling for participant age, with total
neocortical PET amyloid ligand binding (SUVr) entered as the dependent measure was
conducted. Macular RNFL (mRNFL) volume change, over the 27-month study interval,
accounted for 10% of the variance in PET amyloid neocortical binding at the end of the
study (Adj R2 = 0.106, ρ = 0.017; Fig 2). By comparison, change in the GCL over the
same time was related to participant age (ρ=0.05), but not significantly related to PET
amyloid SUVr (ρ=0.78). For all neuronal cell layers, other than the mRNFL, the observed
change over time was not related to Neocortical PET Amyloid SUVr.

3.4. Retinal Layer Change in Relation to Cognitive Performance

There were no significant relationships found between volume reductions for
any of the retinal layers over 27 months and performance on measures of spatial
working memory and learning efficiency (GMLT) or on a measure of word-list
learning and episodic verbal memory (ISLT) (p>0.005).
-------------------------------------------Insert Table 4 About Here
--------------------------------------------

However, an interesting correlation was found between the magnitude of
mRNFL volume reductions and increasing difficulties on the McGurk task of
efficiency for audiovisual integration. That is, individuals with greater volume
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reduction in mRNFL showed reduced sensitivity to the binding strength of the
audiovisual stimulus (ρ = 0.037, 1-tailed; Fig 3).

Discussion

The average RNFL thicknesses for both groups in our study are similar to the
control groups reported by others [5, 39] as well as to the measurements obtained
by Golzan and colleagues in their preclinical AD [14]. Likewise, our OCT
measurements of the GCL and IPL layers are quite similar to those reported by
others [22].
-------------------------------------------Insert Fig. 2. About Here
--------------------------------------------

Of the prior studies we reviewed and described above, Garcia-Martin and
colleagues reported retinal layer thickness values that differed substantially from
both our measurements as well as from most other published reports [20].
Most published research on this topic have relied on cross-sectional study
designs, with measurements of the thickness and volume of various retinal layers
at a single point in time. Such studies are likely to be limited in their ability to
identify retinal markers of the preclinical stage of AD, as such individuals are still
relatively young and such between-groups comparisons have not generally
accounted for a variety of confounding variables including, but not limited to,
effects of sex differences, ethnicity, axial length, optic disc area, and refractive
status on OCT measurements [44, 79, 80, 81].
-------------------------------------------Insert Fig. 3. About Here
--------------------------------------------
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-------------------------------------------Insert Table 5 About Here
--------------------------------------------

Hence, we performed this within-subjects longitudinal study to measure
individuals’ structural parameters that can be reliably re-measured at different
time points using the Eye Tracker software for SPECTRALIS SD-OCT [82]; we
then calculated the difference after 27 months of all measures collected (Table 4)
for the preclinical AD and the healthy control group. To our knowledge, this is the
first attempt to both explore within-subject change in retinal neuronal layer structures, in
the preclinical stage of AD, and to relate any such observed changes to performance on a
cognitive assay that has been shown to be sensitive to detection of early-stage disease
burden. Our findings suggest that a decrease in mRNFL volume is the earliest

detectable structural retinal change associated with AD. Moreover, this change in
mRNFL volume is related with neocortical Aβ accumulation in very early AD
(Fig. 1), even after correcting for expected age-related decline [83] (Table 5). By
comparison, the decrease in GCL volume observed over the same time period was
principally related to the effects of aging (ρ=0.05) rather than due to cortical betaamyloid aggregation (ρ=0.78), at least during this earliest detectable stage of
disease progression.
The macular region of the retina is physiologically very active in healthy
normal eyes [7], and this “hyperexcitation” might be diminishing in the
preclinical stage of AD. In support of this hypothesis, postmortem histological
studies have found prominent pathological alteration of retinal ganglion cells
(RGCs) in the macular region in AD patients [26, 84] as well as a preferential loss
of larger axons, suggesting early involvement of the magnocellular RGCs in AD
as they contribute large caliber fibers to the optic nerve [85]. The RNFL is
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adjacent to the GCL and it is composed largely of ganglion cell axons that are
organized in superior and inferior arcuate bundles, and the papillomacular bundle
(PMB), that lead to the optic nerve. Early in multiple sclerosis there is
demyelination without axonal loss. Likewise, the mRNFL may be thinned due to
demyelination, and possibly only when there is axonal loss will we see loss of
ganglion cells (GCL). Our results suggest early demyelination in the RNFL in the
preclinical stage of AD, and our data confirm at least one other report of mRNFL
changes occuring prior to pRNFL changes in AD [86]. Moreover, there is some
suggestion that this might be most readily observed in the superior quadrant of the
mRNFL [86] and this would make sense in light of at least one clinical report of
preferential inferior visual field loss in AD [87]. However, in a meta-analysis of
17 studies comparing AD patients with healthy controls and five studies
comparing individuals with mild cognitive impairment (MCI) with controls, there
were significant decreases in all four quadrants compared to controls, thus
suggesting that the degenerative process affects the entire macular region [8].
There have now been ample work showing that there is GCL thinning
observed in the symptomatic stage of AD [5,15, 22]. Moreover, Martin et al. [20]
studied 150 patients with AD and 75 age-matched controls to model how changes
in RNFL and other neuronal cell layers’ thicknesses are associated with disease
duration and severity. This work suggests that there is axonal degeneration in the
RNFL early in the disease followed by degenerative changes to the cell bodies in
the GCL and then progression to deeper neuronal layers [20]. This progressive
pattern of mRNFL loss prior to GCL loss is further confirmed by our results
reported above. Additionally, we found that only loss of mRNFL tissue, and not
loss in any other neuronal layer, was correlated with beta-amyloid protein
113

aggregation in the cerebral cortex.

These results fit nicely with data from a large

population-based epidemiological study (Rotterdam Study, 2007-2012) showing
that having a thinner RNFL at a baseline exam was significantly associated with
increased risk of later developing dementia [88].

4.1. Relationship of RNFL Thinning to Cognitive Function in Preclinical AD
Contrary to a few prior reports [49, 50, 89], we did not observe any
correlation between any retinal layer changes and change in either episodic verbal
memory (ISLT) or for performance on a working memory and reasoning task for
visuospatial information (GMLT). However, because white matter degeneration is
readily observable in the early stages of AD [90], and the cerebral white matter is
principally composed of myelinated axons and glial cells – as is the retinal RNFL –
we chose to administer a cognitive task that is putatively sensitive to functional
disruption of corticocortical connections caused by disruption of white matter
integrity [60]. Both prodromal and preclinical AD patients with high beta-amyloid
burden have been previously found to display changes in audiovisual integration
efficiency that are likely due to AD-related disruptions in functional connectivity
between posterior sensory regions. Using McGurk-like audiovisual speech stimuli
(i.e., video clips of an individual mouthing a speech sound while the audio channel
provides either consistent or inconsistent auditory speech information), we found
that greater volume reduction in mRNFL was significantly associated with reduced
sensitivity to the binding strength of the audiovisual stimulus (Fig. 2). While
healthy individuals typically show faster response times to consistent stimuli than
inconsistent stimuli (i.e., response times are faster when the auditory and visual
components provide the same compared to conflicting speech information), we
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found that this response time difference decreased with greater RNFL volume
reduction. In fact, greater volume reduction in mRNFL was significantly
associated with reduced sensitivity to the binding strength of the audiovisual
stimulus, suggesting that mRNFL volume reduction is related to white matter loss.
Consistent with previous findings [60], this reduced sensitivity may reflect subtle
disruptions of corticocortical projections within unimodal and heteromodal sensory
cortices that indicate individual risk of AD.

4.2. Change in Retinal Neuronal Layers, Other than the RNFL, in Preclinical AD
As noted above, we observed significant changes in ONL (p=0.026) and
IPL volumes (p=.002), and inferior quadrant thicknesses for these same layers,
respectively (ρ=.026; ρ=0.028), in the preclinical AD group compared to the
controls, over 27 months. However, neither of these changes were related to PET
imaging severity of neocortical amyloidosis at the end of the 27-month interval
(Table 5). We have previously reported, with the same cohort of subjects at their
baseline examinations, an increase in the IPL volume in preclinical AD that may
be related to either Aβ deposition and/or an inflammatory process [16]. Twentyseven months later we have now found evidence of tissue loss in the IPL, within
our preclinical group relative to controls, suggesting that although there may be an
initial early stage of IPL volume increase due to an inflammatory process, there is
nonetheless some volume loss in this structure over continued disease progression.
Finally, the ONL consists of photoreceptor cell bodies and thinning of this
layer has previously been shown in patients with age-related macular degeneration
in association with tears in the retinal pigment epithelium [91]. In the context of
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early AD, we believe that our observation of tissue loss in the ONL could suggest
retrograde transsynaptic degeneration, but future analysis would be necessary.

Conclusion and Future Directions
To our knowledge this is a first report of a within-subjects, prospective,
longitudinal study of retinal anatomic changes in the preclinical stage of AD. We
have found that thinning of the mRNFL may be the earliest anatomic marker of
retinal neuronal loss in the preclinical stage of AD, and such loss appears to
account for 10% of the variance in observed PET imaging measurement of
neocortical amyloidosis. Whereas most reports have relied on clinical
examinations for determining disease burden, our study used PET imaging
biomarker of disease burden. Our study is limited by a small sample size, and so
these findings require replication in a larger patient population. Secondly, we
chose to recruit participants who were at high risk for the very early stages of the
disease, that is, during a prodromal stage that is defined by a relative absence of
readily identifiable cognitive and/or functional impairments, as well as by
biomarker evidence of disease burden that is subtle and for which clear diagnostic
criteria have not yet been established [46]. Third, retinal imaging is not only being
studied to identify novel biomarkers for this neurodegenerative disease, but
changes in the GCL and RNFL thickness have also been reported in Parkinson’s
disease and multiple sclerosis [92, 93, 94, 95].
Future work on this topic will require the recruitment of larger populations
of participants, across the entire disease severity spectrum (from healthy controls
to mild AD), and ideally such a large cohort should be followed for an even longer
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time interval in order to better model the natural history of retinal anatomic
changes over the entire course of disease progression. Additional imaging
modalities should be included in such a study (e.g., OCT Angiography), as retinal
blood flow appears to be reduced in MCI and AD [19,40], and the disease has been
associated with a retinal venular stenosis, reduced complexity of the branching
pattern and geometry, and reduced tortuous venules [96]. We also would
recommend inclusion of scanning laser polarimetry (SLP) methods to measure
RNFL retardance in preclinical AD because, in glaucoma, RNFL retardance seems
to occur before actual RNFL thinning [97]. The mechanisms of glaucomatous
injury appear to be related to damage the integrity of axonal cytoskeletal
ultrastructure prior to the point of RNFL thinning detectable by OCT [97,98,99].
The axonal cytoskeleton disruption that causes RNFL retardance [97] may possibly
be similar to the effects of Aβ plaques and tau tangles in the AD brain.
These results point to the first retinal anatomic changes occurring in the
early stages of AD. Characterizing retinal changes at this stage with a non-invasive
method will facilitate the search for treatments that can delay or stop the
progression of AD. This study also demonstrates that, although many different
approaches have already been taken in this field, there is still much more to
explore and much that we do not understand with respect to the effects of
Alzheimer’s disease on the retina.
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Table 1. Review of Papers published until 25 July 2017, using the search terms
“Alzheimer’s” and “retinal layer”.

Publication

Cunha et al.,
2017 [13]
Golzan et al.,
2017 [14]
Ferrari et
al.,2017 [15]

Layers

Results

pRNFL and
retinal

thinner pRNFL, and
superior pericentral
and peripheral retinal
sectors

RNFL and
GC-IPL
pRNFL and
GC-IPL

RGCL thinner, no
difference in RNFL

thinning

Cross
sectional

Yes

Subjects

AD

Age
matched
Controls
Yes, age
as
covariate

Yes

Yes, age
preclinic
as
al AD
covariate

Yes

Yes, age
MCI and
as
AD
covariate

Yes

preclinic
al AD

Yes, age
MCI and
as
AD
covariate

Snyder et
al.,2016 [16]

IPL

thicker in preclinical

Choi et al.,
2016 [17]

pRNFL and
GC-IPL

thinner in the
temporal quadrant

Yes

AD

Yes, age
as
covariate

Yes

Trebbastoni
et al., 2016
[18]

pRNFL

thinner

No, 1
year

Feke
etal.,2015
[19]

pRNFL

no difference

Yes

MCI and
AD

Yes

Cunha et
al.,2016 [5]

Macular and
GCL+ (GCIPL)

thinner

Yes

AD

Yes

RNFL, GCL and IPL
thinner

Yes

AD

Yes

Pillai et al.,
2016 [21]

pRNFL,
macular and
GC-IPL

no difference

Yes

MCI and
AD

Yes

Eraslan et al.,
2015 [22]

pRNFL and
GCC (RGCL)

thinner

Yes

AD

Yes

Güneş et al.,
2015 [23]

pRNFL

thinner

Yes

AD

Yes

Cesareo et al.,
2015 [24]

pRNFL

thinner

Yes

AD

Yes

Garcia-Martin pRNFL, GCL,
et al., 2016
INL, IPL,
[20]
ONL, OPL
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SalobrarGarcia et al.,
2015 [25]

pRNFL and
macular

thinner

Yes

AD

Yes

La Morgia et
al.,2016 [26]

pRNFL

age-related thinner

Yes

AD

Yes, age
as
covariate

Shi et al.,
2016 [27]

pRNFL

thinner in the inferior
quadrant

No, 27
months

AD

Yes

pRNFL

thinner in the
superior and superior
quadrant

Yes

MCI and
AD

Yes

Oktem et al.,
2015 [29]

pRNFL

thinner, but no
differences between
MCI and AD

Yes

MCI and
AD

Yes

Gao et al.,
2015 [30]

pRNFL and
macula
lutea

thinner specially in
MCI

Yes

Yes, age
MCI and
as
AD
covariate

pRNFL and
GC-IPL

thinner pRNFL
superior quadrant,
MCI had thinner GCIPL

Yes

MCI and
AD

Yes

pRNFL

thinner in nasal
superior

Yes

AD

Yes, age
as
covariate

Bambo et al.,
2014 [33]

pRNFL

thinner in the inferior
and inferiotemporal

Yes

AD

Yes

Marziani et
al., 2013 [34]

pRNFL +GCL

thinner

Yes

AD

Yes

Kirbas et al.,
2013 [35]

pRNFL

thinner

Yes

AD

Yes

Moschos et
al., 2012 [36]

pRNFL and
macular

thinner

Yes

AD

Yes

Kesler et al.,
2011 [37]

pRNFL

thinner

Yes

MCI and
AD

Yes

Lu et al., 2010
[10]

pRNFL

thinner

Yes

AD

Yes

Chi et al.,
2010 [38]

pRNFL

thinner

Yes

AD

Yes

Liu et al.,
2015 [28]

Cheung et al.,
2015 [31]
Kromer et al.,
2014 [32]
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pRNFL

thinner, but no
differences in MCI
and AD

Yes

MCI and
AD

Yes

Berisha et
al.,2007 [40]

pRNFL

thinner in the
superior quadrant

Yes

AD

Yes

Iseri et al.,
2006 [9]

pRNFL and
macula

thinner

Yes

AD

Yes

Parisi et al.,
2001 [41]

pRNFL

thinner

Yes

AD

Yes

Kergoat et al.,
2001 [42]

pRNFL

No differences

Yes

AD

Yes

pRNFL

thinner in the
superior quadrants

Yes

AD

Yes

Paquet et al.,
2007 [39]

Hedges et al.,
1996 [43]

Abbreviations: AD, Alzheimer's disease; GCL, ganglion cell layer; GC-IPL, ganglion
cell–inner plexiform layer complex; INL, inner nuclear layer; IPL, inner plexiform layer;
MCI, mild cognitive impairment; ONL, outer nuclear layer; OPL, outer plexiform layer;
pRNFL, peripapillary retinal nerve fiber layer; RGCL (or GCC), retinal nerve fiber layer–
GCL complex; RNFL, retinal nerve fiber layer.
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Number of female
Number of Ɛ4 carriers

Number of years
Number of years
Standardized Uptake Value
ratio
Total Score
Body Mass Index
Total Score
Total Score
Total words recalled
Total number of errors

Sex
APOE

Age
Education
Florbetapir PET
SUVr
GDS
Body Mass Index
MAC-Q
MMSE
ISLT Total Recall
GMTL Total Errors

Main Outcome

Aβ+ (n=15)
N(%)
11 (73.3)
8 (53.3)
Mean (SD)
68.25 (5.81)
17.75 (3.91)
1.32 (0.18)
0.91 (0.94)
26.58 (4.36)
21.97 (2.81)
28.72 (1.85)
26.00 (3.52)
8.27 (3.53)

Full sample (n = 56)
N(%)
35 (62.5)
27 (4.2)
Mean (SD)
65.36 (5.55)
17.31 (2.77)
1.02 (0.2)
1.4 (1.87)
26.69
21.90 (3.08)
29.25 (1.29)
26.07 (3.79)
8.40 (5.31)

1.52 (2.02)
26.86 (6.05)
21.90 (3.08)
29.38 (1.10)
26.09 (3.90)
8.44 (5.71)

Aβ- (n=41)
N(%)
24 (58.5)
19 (46.3)
Mean (SD)
64.56 (5.26)
17.19 (2.42)
0.94 (0.09)
.34
.879
.527
.132
.944
0.92

p
.311
.643
p
.06
.54
.000
0.34
0.35
0.23
0.49
0.02
0.03

Cohen’s d
0.68
0.19
3.17

Table 2. Demographic Characteristics
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Abbreviations: APOE, apolipoprotein E; GDS, Geriatric Depression Scale; GMLT,
GrotonMaze Learning Test; ISLT, International Shopping List Test;MAC-Q, Memory
Complaint Questionnaire; MMSE, Mini–Mental State Examination; PET, positron
emission tomography; SUVr, standardized uptake value ratio.Bold values denote
significant group differences.
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Table 3. Baseline Retinal Measures by Analysis Group
Retinal Measures

Preclinical (n=15)

Control (n=41)

p-value

total volume (mm3)

0.227±0.021

0.231±0.025

0.283

average thickness

28.58±3.08

28.92±3.57

0.383

Inferior

33.04±3.53

32.69±4.39

0.599

Nasal

28.87±3.87

29.12±4.70

0.433

Superior

32.12±4.42

32.74±5.10

0.353

Temporal

20.29±1.20

21.12±2.76

0.157

average thickness

103.36±5.36

101.48±9.76

0.726

Inferior

134.25±8.15

129.05±13.49

0.882

Nasal

83.04±17.36

85.3±19.88

0.368

Superior

127.45±10.32

124.17±13.72

0.765

Temporal

67.86±11.07

67.71±11.68

0.612

total volume (mm3)

0.444±0.018

0.428±0.029

0.942

average thickness

51.15±2.20

48.94±3.61

0.964

Nasal

53.60±2.03

51.23±3.70

0.970

Temporal

50.90±3.77

49.01±4.41

0.889

Superior

48.75±4.01

48.08±3.88

0.683

Inferior

51.35±1.94

47.42±4.18

0.997

total volume (mm3)

0.353±0.030

0.357±0.027

0.339

average thickness

39.40±3.67

39.18±3.27

0.578

Inferior

39.00±4.92

37.54±3.78

0.862

Nasal

40.37±3.37

40.66±3.66

0.403

Superior

37.50±3.63

37.39±3.68

0.534

Temporal

40.71±4.73

41.10±3.28

0.369

total volume (mm3)

0.294±0.373

0.301±0.037

0.031

average thickness

31.32±3.40

32.10±3.89

0.267

mRNFL

pRNFL

GCL

IPL

OPL
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Inferior

30.91±3.38

31.51±4.68

0.410

Nasal

33.87±6.19

35.33±7.42

0.620

Superior

30.16±3.36

30.65±3.42

0.442

Temporal

30.33±3.54

30.88±3.50

0.483

total volume (mm3)

0.338±0.020

0.348±0.028

0.124

average thickness

38.08±1.39

38.54±3.13

0.312

Inferior

37.54±1.23

38.45±3.04

0.158

Nasal

39.70±1.55

39.67±4.66

0.510

Superior

38.08±1.81

38.70±3.18

0.645

Temporal

37.00±2.83

37.34±3.37

0.372

total volume (mm3)

0.679±0.066

0.671±0.067

0.644

average thickness

67.09±7.02

66.48±7.04

0.604

Inferior

64.16±7.38

64.00±7.94

0.529

Nasal

67.92±8.66

64.51±8.97

0.877

Superior

68.08±7.14

68.34±6.63

0.453

Temporal

68.20±7.17

69.09±7.68

0.361

INL

ONL

Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer
plexiform layer; pRNFL, peripapillary retinal nerve fiber layer.
NOTE. All measurements, for each layer, are acquired from all radial quadrants from the
ETDRS circular grid, with a 3.45-mm diameter centered on the fovea. Data from both eyes
are averaged. Values are mean ± SD. All values are in micrometer (mm), unless otherwise
indicated.
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Table 4. Change over 27 Months by Groups
Pre-Clinical AD
(N=15)

Healthy Controls
(N=41)

-0.032±0.003

-0.019±0.003

0.050

0.550

Average

-4.45±3.68

-3.26±3.94

0.448

0.3072

Inferior

-4.45±3.314

-3.09±4.323

0.656

0.3352

Superior

-5.10±3.671

-4.50±4.845

0.348

0.1318

Nasal

-4.50±3.801

-2.41±4.416

0.196

0.4917

Temporal

-3.75±3.936

-3.04±2.212

0.77

0.2528

Average

-3.389±2.058

-1.181±4.057

0.060

0.605

Inferior

-1.39±6.22

1.63±9.10

0.386

0.357

Superior

-3.33±11.92

-1.41±14.10

0.631

0.141

1.67±5.97

3.81±7.79

0.381

0.290

-1.04±4.13

0.18±4.51

0.400

0.276

-0.016±0.016

-0.011±0.019

0.206

0.29

Average

-1.96±2.59

-1.34±3.03

0.590

0.209

Inferior

-2.4±2.97

-0.86±3.38

0.091

0.464

Superior

-1.0±3.51

-1.43±4.18

0.614

0.107

-0.65±3.54

-0.05±3.54

0.321

0.166

-3.8±2.87

-3.02±3.83

0.590

0.210

0.017±0.04

-0.003±0.032

0.965

0.603

Average

0.843±-3.05

-0.605±2.89

0.932

0.495

Inferior

0.75±3.51

-0.84±2.59

0.956

0.566

Superior

0.5±3.37

-0.23±3.57

0.262

0.208

Nasal

-0.83±4.88

-1.77±6.85

0.329

0.144

Temporal

2.95±4.31

0.43±4.53

0.040

0.562

-0.029±0.030

-0.007±0.035

0.026

0.646

Location

p-value

Effect Size
(Cohen’s d)

mRNFL
Volume (mm3)

pRNFL

Nasal
Temporal
GCL
Volume (mm3)

Nasal
Temporal
OPL
Volume (mm3)

ONL
Volume (mm3)
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Average

-1.61±2.86

-0.068±3.39

0.077

0.469

Inferior

-2.25±5.66

0.84±4.54

0.026

0.644

Superior

-1.70±2.60

-1.43±3.73

0.405

0.078

0.87±3.58

2.92±7.27

0.176

0.305

-3.37±7.62

-2.60±5.52

0.347

0.128

-0.014±0.015

-0.006±0.011

0.020

0.686

Average

-1.80±1.91

-1.06±1.66

0.099

0.427

Inferior

-2.41±3.32

-0.84±2.17

0.028

0.638

Superior

-1.91±1.50

-1.06±2.49

0.133

0.368

Nasal

-0.95±2.23

-1.07±2.011

0.567

0.055

Temporal

-1.91±2.11

-1.29±2.57

0.22

0.250

0.004±0.019

0.001±0.022

0.64

0.12

Average

2.04±2.14

2.30±5.50

0.43

0.276

Inferior

2.04±2.32

0.19±2.67

0.98

0.708

Superior

0.33±1.91

0.011±2.38

0.665

0.140

0±1.97

0.47±3.94

0.34

0.131

0.70±2.75

0.39±2.25

0.655

0.131

Nasal
Temporal
IPL
Volume (mm3)

INL
Volume (mm3)

Nasal
Temporal

Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer
plexiform layer; pRNFL, peripapillary retinal nerve fiber layer.
NOTE. All measurements, for each layer, are acquired from all radial quadrants from the
(ETDRS) circular grid, with a 3.45-mm diameter centered on the fovea. Data from both
eyes are averaged. Values are mean ± SD, unless otherwise indicated. All values are in
micrometer (mm), unless otherwise indicated.
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Table 5. Multivariate linear regression model of volume (mm3), for different
locations
Location

Volume
mRNFL
GCL
OPL
ONL
IPL
INL

Coef. Neocortex

Neocortex

SUVr

SUVr P-Value

-0.228
-0.003
2.05
-0.0267
-0.014
0.026

0.041
0.78
0.84
0.423
0.144
0.08

Coef. Age

0.00009
-0.0008
-0.034
0.00026
-0.0034
-0.005

Age P-Value

0.024
0.05
0.691
0.834
0.196
0.26

Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform
layer; mRNFL, macular retinal nerve fiber layer; ONL, outer nuclear layer; OPL, outer
plexiform layer; PET, positron emission tomography; pRNFL, peripapillary retinal nerve
fiber layer; SUVr, standardized
uptake value ratio.
NOTE.Values are in cubic millimeter (mm3) for the coefficients. Controlling for
participants’ age, with total neocortical PETamyloid ligand binding (SUVr) entered as the
dependent measure.
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Fig. 1. Representative cross-sectional OCT image through macular region, with the fovea in
the center (green line). Labels are shown for the RNFL, GCL, and IPL. The mean macular
thickness of each retinal layer was measured within four sectors (superior, inferior, nasal, and
temporal), extending 3.45 mm from the center of the fovea, leading to a macular volume
measurement for each retinal layer. Mean volumes (mm3) for each layer and thickness (mm)
for each quadrant (right and left eyes averaged) were computed for both the baseline and the
27-month time points. Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer;
OCT, optical coherence tomography; RNFL, retinal nerve fiber layer.

Linear Fit: Adj R2 = 0.106, ρ < 0.017
Fig. 2. Relationship between macular RNFL volume change over 27 months
and total neurocortical amyloid aggregation (18F-florbetapir PET SUVr) at
end of study. Abbreviations: PET, positron emission tomography; RNFL,
retinal nerve fiber layer; SUVr, standard uptake value ratio.
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Linear Fit: Adj R2 = 0.098, ρ < 0.037 (1-tailed)
Fig. 3. Relationship between macular RNFL volume change over 27 months and performance
on a measure of audiovisual integration efficiency (“McGurk Task”[60]). Abbreviation:
RNFL, retinal nerve fiber layer.
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Abstract

Introduction: Retinal and cerebral microvasculature share similar embryological
origins, anatomical features and physiological properties; and reduced retinal blood
flow has been reported previously in mild cognitive impairment (MCI) and
Alzheimer’s disease (AD), relying on both Doppler ultrasonography and optical
coherence tomography angiography (OCTA) imaging technologies. The present study
relies on OCTA to explore this same question in the preclinical AD stage of the
disease.
Methods: Forty-eight adults (mean age = 68.76 years) with well-established risk
factors for AD were recruited. Florbetapir amyloid PET scans were obtained and
neocortical PET and standardized uptake value ratios (SUVr) threshold of 1.1 or
greater was used to identify individuals with preclinical AD. Retinal OCTA images
were captured using an AngioVue system (Optovue, Fremont, CA, USA), and the Df
was measured in linearized superficial microvascular plexus images to measure the
space-filling linear extension of the large vessels.

Results: The mean Df of preclinical AD subjects (N = 10) was significantly lower
(ρ=0.005), with substantially greater variability, than that of healthy controls in the
macular region (N = 28) (heteroscedastic Student’s t-test, 2-tailed). For the
peripapillary region there was no significant difference (ρ=0.12) between both groups.

Conclusion: Our findings suggest that individuals at high-risk for preclinical AD have
less density and complexity of retinal microvascular networks in the superficial
vascular plexus in the macular region than healthy controls. Retinal vascular
distribution and blood flow are already altered during the very earliest stages of AD.

Keywords: angio-OCT; retinal; blood flow; preclinical; Alzheimer’s; fractal
dimension
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Introduction
The co-occurrence of various cerebrovascular changes and Alzheimer’s
disease (AD) is both well established and interdependent (1, 2). Whereas unimpaired
cerebral blood flow (CBF) supports healthy neural activity and function, reduced CBF
has been repeatedly observed in mild cognitive impairment (MCI) (3-9). Moreover,
vascular density is significantly reduced, specifically in the basal forebrain region and
the hippocampus of AD brains (10), and the capillary ultrastructure in the limbic
cingulate cortex is severely compromised (11). Such cerebral capillary damage can
lead to pathophysiological consequences, such as compromised nutrient transport,
insufficient neuronal metabolism and subsequent cognitive disturbances; it should be
considered a significant factor in the development of AD (11-14). AD has been
associated with decreased anatomic complexity (e.g., tortuosity) of the cerebral
vasculature, with venous collagenosis, string vessels (capillary remnants), decreased
vascular density, and with concomitant microembolic brain injuries (15).
Diminished or altered CBF has not been conclusively shown to occur in the
preclinical stage of AD following National Institute on Aging – Alzheimer’s
Association (NIA-AA) criteria (16), and AD-related perfusion studies are largely
restricted to correlating CBF with genetic and cognitive factors (17). For example,
Okonkwo and colleagues (18) reported decreased CBF in right superior and middle
frontal cortices for middle-aged adults with familial history of AD compared to agematched cognitively normal subjects. Moreover, relative decrements in CBF were
associated with modest impairments in memory function (18, 19) and general
cognitive performance (20,21). Several recent publications have suggested specific
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cerebral perfusion markers as potential indicators for amyloidosis and early disease
detection (22-24).
The measurement of blood flow in the retina is likely to be very closely related
to, and indicative of, neocortical blood flow. Retinal angiographic imaging allows for
non-invasive access to the microcirculation, and the retinal vasculature shares similar
embryological origin, anatomical features, and physiology with the cerebral
vasculature (25-30). Reduced retinal blood flow has been reported in MCI and AD
patients using Doppler methodology (31,32), and such retinal abnormalities as
vascular attenuation, increased variability in vessel widths, reduced complexity of the
branching pattern and less tortuous venules have been found in AD (33).
With very recent advances in angiographic optical coherence tomography
imaging (OCTA), the retinal microvasculature can now be visualized without the need
for intravenous administration of a contrast dye agent (34), to provide a range of
measures such as the width of the lumen of vessels as small as 6-8 µm, vessel
tortuosity and bifurcations, and these images can be subjected to a broad array of
analytic approaches. OCTA has shown potential efficacy in the evaluation of common
ophthalmologic diseases (35). In diabetic retinopathy, the foveal avascular zone (FAZ)
and parafoveal vessel density provide a detailed view of the retinal vasculature and
have been measured with high reproducibility by OCTA in both superficial and deep
plexus (36). OCTA can also detect changes in choroidal blood vessel flow in age
related macular degeneration. Narrowing of central retinal venous column diameter
has been reported in AD and MCI (31,32).
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Although there are many potential approaches to the extraction of important
data from highly complex OCTA retinal images, one approach that relies of fractal
geometry and the computation of fractal dimension (Df) values to objectively score
the complexity and density of vascular branching, has already been used with apparent
success. Using this very approach, Jiang and colleagues reported microvascular loss,
beyond what is seen as a consequence of normal aging, in patients with MCI and AD
(37). Since there remains a clear need for reliable, non-invasive techniques for
screening potential high-risk individuals who may be in the earliest stages of AD, we
decided to adopt this same analytic approach to explore retinal blood flow changes in
the preclinical stage of AD. We have not been able to identify any other published
literature that has addressed this question at such an early stage of the disease process.

.
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Methods

Participants
A total of Fifty-six adults aged between 55 and 75 years (mean age = 65.36
years old) with two well-established risk factors for AD, namely, a self-reported firstdegree family history of the disease and self-identification of subjective memory
concerns, were recruited using a selection process described previously (38). All
participants underwent a detailed medical screening interview. Exclusion criteria
included a diagnosis of MCI or AD following NIA-AA diagnostic criteria (39,40),
history of neurological or psychiatric disorder, any significant systemic illness or
unstable medical condition (e.g., active cardiovascular disease), and current use of any
medications known to affect cognition (e.g., use of sedative narcotics). Subjects with
histories of cataract surgery, corneal LASIK surgery, age-related macular
degeneration, glaucoma, diabetic retinopathy or subjects with known ophthalmic
pathology were excluded.
Inclusion criteria included a score on the mini-mental state examination
(MMSE) > 27 and performance within normal limits on the International Shopping
List Test (ISLT; www.cogstate.com) as a measure of verbal episodic memory; and the
Memory Complaint Questionnaire (MAC-Q) (41,42). All participants live
independently, most were engaged in full-time or part time employment, and many
were caretakers for a parent with AD.
From this larger sample, we identified 15 participants who were categorized as
presenting with preclinical stage disease based on evidence of elevated neocortical
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beta-amyloid burden as determined by PET amyloid imaging (16, 39). The study was
approved by and complied with the regulations of Rhode Island Hospital’s
Institutional Review Board, and all participants provided written informed consent in
accordance with the Declaration of Helsinki, and this study complied with HIPAA
regulations.

Aβ PET imaging
To assess neocortical amyloid burden, all participants had an Aβ PET scan. A
370MBq (10 mCi 1/2 10%) bolus injection of 18F-florbetapir was administered
intravenously. Approximately 50 minutes’ post-injection, a 20-minute PET scan was
performed with head CT scan for attenuation correction purposes. Images were
obtained using a 128X128 matrix and reconstructed using iterative or row action
maximization likelihood algorithms. PET standardized uptake value (SUV) data were
summed and normalized to the whole cerebellum SUV, resulting in a region-tocerebellum ratio termed SUV ratio (SUVr).
A SUVr threshold of 1.1 or greater was used to discriminate between Aβ+ and Aβ-.
These SUVr calculations were performed using the MIMneuro software, with a
normative database of 74 healthy normal individuals (48 males, 26 females), aged
between 18–50 years, who all had negative amyloid scans on visual assessment (43).
For all cases, Aβ positivity was confirmed by consensus over-read by two boardcertified radiologists who were also board certified in nuclear medicine
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Angio-OCT
OCTA images were captured using AngioVue (Optovue, Fremont, CA, USA).
OCTA volume scans were obtained horizontally and vertically to decrease motion
artifacts and fixation changes. Split-spectrum amplitude-decorrelation angiography
was used to detect flow and produce OCTA images and en face sections. A 3x3volume scan centered on the fovea and in the optic nerve were obtained with an Ascan rate of 70kHz. Each volume scan consists of 304x304 A-scans with 2 consecutive
B-scans at each position. Two right-angled OCT-A volume scans are performed for
orthogonal registration to correct for motion artefacts. Split-spectrum amplitudedecorrelation angiography was used to detect flow and produce OCTA images and en
face sections. We selected the right eye OCTA of each participant for the fovea and
optic nerve images to realize the Df analysis, using the superficial microvascular
plexus images (3 µm below internal limiting membrane and 15 µm below inner
boundary of inner plexiform layer).
The Df was measured in linearized vascular images in order to measure the
space-filling linear extension of the vessels. Df was estimated with a computer
program implementing the method of boxcounting. With this method, the image is
overlaid with series of square boxes of decreasing size (s = 512, 256, 128, . . . 1, where
s denotes a single pixel), and the number of boxes [N(s)] containing at least one black
pixel is counted. The negative value of the least squares regression slope of the plot of
log N(s) versus log s yields Df (44). The images were analyzed removing the small
vessels, keeping only vessels with a diameter of more or equal to 25 μm (37).
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Statistical Analysis
Demographic characteristics of the preclinical AD and healthy controls
subjects were compared (Tables 1 and 2) for those individuals with good quality
OCTA images in the macular region (N=38) and peripapillary region (N=48). To
compare the variables Sex and APOE, the freq procedure was done in SAS and the
Fisher’s exact test was used due to the small sample sizes. For all the other
demographic and cognitive variables: Age, Education, Florbetapir PET SUVr, MACQ, MMSE and ISLT Total recall, the means ± SD were computed for each group and
t-tests were used to identify group differences.
For each individual, the Df (with a grid size of 64 pixels) for the superficial
vascular plexi, in the macular (centered on the fovea) and peripapillary (centered on
optic nerve head) regions of the right eye retinas, were computed (mean and standard
deviation (SD) of the measurements). Only good quality images were included (that is,
those that were free of substantial imaging artefacts), resulting in 10 participants for
the preclinical AD group and 28 healthy controls for the macular region analyses, and
an additional 10 healthy control cases for the peripapillary region analyses. The
normality of the Df measurement distributions, for both groups, were verified with the
Shapiro-Wilks test, with normally distributed data then analyzed using the t-test
pooled method and non-normally distributed data analyzed using the Satterthwaite
method.
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Results

Of the 38 participants with high-quality macular OCTA images, there were no
significant differences between Aβ+ and Aβ- groups with respect to sex (ρ =0.69).
Likewise, there were no group differences in the proportion of individuals with the
APOE Ɛ4 genetic risk marker for AD (ρ =0.269). The mean age of the total sample
was 69.36 years old and this sample had an average of 17.25 years of education with
no education difference between groups (ρ =0.64). All relevant demographic
information, for both groups, are provided below in Table 1. There were no group
differences with respect to general cognitive function or subjective memory
complaints (MMSE and MAC-Q) nor on a performance measure of episodic verbal
memory (ISLT). By definition, both groups significantly differed with respect to
neocortical amyloid aggregation as measured via PET imaging (ρ = 0.000).
-------------------------------------------Insert Table 1 About Here
-------------------------------------------Of the 48 participants with high-quality peripapillary OCTA images (Table 2),
there were similarly no significant differences between Aβ+ and Aβ- groups with
respect to sex (sex (ρ =0.281). Likewise, there were no group differences in the
proportion of individuals with the APOE Ɛ4 genetic risk marker for AD (ρ =0.151).
The mean age of the total sample was 69.76 years old and this sample had an average
of 17.45 years of education with no education difference between groups (ρ =0.789).
There were no group differences with respect to general cognitive function or
subjective memory complaints (MMSE and MAC-Q) nor on a performance measure
of episodic verbal memory (ISLT). By definition, both groups significantly differed
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with respect to neocortical amyloid aggregation as measured via PET imaging (ρ =
0.000).
-------------------------------------------Insert Table 2 About Here
-------------------------------------------Results of the region-based fractal analysis (Df values) of linearized vascular
patterns extracted from OCTA of preclinical AD and healthy controls, are summarized
in Figure 1 for the macular region and Figure 2 for the peripapillary region. In the
macular region, mean ± SD of healthy controls was 1.5896± 0.0999 and of preclinical
AD was 1.3860±0.1799. The mean Df in the macula of preclinical subjects (N=10) is
both significantly lower (ρ=0.005), and there is clearly greater variability in these
measurements, as compared to the healthy controls (N=28).
-------------------------------------------Insert Figure 1 About Here
-------------------------------------------In the peripapillary region, mean ± SD of healthy controls was 1.4290± 0.0975
and of preclinical AD was 1.3744±0.1064. The mean Df of preclinical subjects (N=10)
in the peripapillary is not significantly different (ρ=0.12) than that of healthy controls
(N=38).
-------------------------------------------Insert Figure 2 About Here
--------------------------------------------
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Conclusion

The observed decrement in vascular bed density and complexity, as measured
by the computation of the Df for each image of the superficial and/or deep vascular
plexi, was reported to be reduced by 0.05 in AD and 0.03 in MCI, compared to elderly
controls (37). We have found that at any even early stage of disease progression (in
preclinical AD) the microvascular network loss in the superficial capillary plexus for
the macular region was similarly reduced compared to healthy controls (ρ=0.005) (see
examples in Figure 3).
-------------------------------------------Insert Figure 3 About Here
--------------------------------------------

These results fit nicely with our recent report that a volume reduction in the
macular retinal nerve fiber layer (RNFL) appears to be the location of the earliest
observable structural (retinal cell layer) change in the preclinical stage of AD (45). As
we previously described, the macular region of the retina is physiologically very active
in healthy normal eyes (46), and this “hyperexcitation” might be diminishing in the
preclinical stage of AD. Postmortem histological studies have revealed prominent
pathological alteration of retinal ganglion cells (RGCs) in the macular region in
clinical AD patients (47,48). However, in the preclinical disease stage we may be
observing either demyelination or loss of axons in the RNFL, prior to any loss of cell
bodies in the ganglion cell layer (GCL) (45).
The superficial microvascular plexus (SVP) is supplied by the central retinal artery
and composed of larger arteries, arterioles, capillaries, venules and veins that primarily
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course through the GCL (49). Primate histology demonstrated that the SVP supplies
all other vascular plexi through vertical pre-capillary arterial segments, which
typically ascend to the nerve fiber layers and descend to the deeper layers (50,51).
Reduced vascular density in the SVP likely leads to degradation in blood flow
throughout the in other parts of the retina and, hence, might directly contribute to
continued axonal loss as well as GCL thinning in AD.
This is a small experimental study with a limited sample size, but we believe
that these results fit nicely with our emerging understanding of early retinal changes in
the preclinical stage of AD, and we are now planning to replicate this work in a much
larger longitudinal natural history study, with a participant cohort that will span the
entire spectrum of the AD severity range.
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Table 1. Demographic Characteristics for Subjects with Acceptable Quality OCTA
Imaging in the Macular Region
Main Outcome

Full sample
(n = 38)

Aβ+ (n=10)

Aβ- (n=28)

N(%)

N(%)

N(%)

ρ

Sex

Number of
female

27 (71.34)

8 (80)

19 (67.86)

.69

APOE

Number of Ɛ4
carriers

19 (50)

7 (70)

12 (42.86)

.269

Mean (SD)

Mean (SD)

Mean (SD)

ρ

Age

Number of
years

69.36 (5.20)

71.4 (5.66)

68.64 (4.93)

.153

Education

Number of
years

17.25 (2.71)

17.12 (2.47)

17.6 (3.43)

.64

Florbetapir
PET SUVr

Standardized
Uptake Value
ratio

1.03 (0.17)

1.29 (0.13)

0.94 (0.07)

.000

MAC-Q

Total Score

25.5 (3.20)

26.6 (2.36)

25.10 (3.40)

.21

MMSE

Total Score

29.10 (1.07)

28.7 (1.25)

29.25 (0.98)

.162

ISLT Total
Recall

Total words
recalled

25.92 (4.23)

24.10 (4.7)

26.78 (3.84)

.080

*Note: SUVr = standardized uptake value ratio; MAC-Q= Memory Complaint Questionnaire;
MMSE = Mini Mental State Examination; ISLT = International Shopping List Test

159

Table 2. Demographic Characteristics for Subjects with Acceptable Quality OCTA
Imaging in the Peripapillary Region
Main Outcome

Full sample
(n = 48)

Aβ+ (n=10)

Aβ- (n=38)

N(%)

N(%)

N(%)

ρ

Sex

Number of
female

30 (62.5)

8 (80)

22 (57.89)

.281

APOE

Number of Ɛ4
carriers

24 (50)

7 (70)

15 (39.47)

.151

Mean (SD)

Mean (SD)

Mean (SD)

ρ

Age

Number of years

68.76 (5.30)

71.4 (5.66)

68.07 (4.95)

.104

Education

Number of years

17.45 (2.82)

17.12 (2.47)

17.32 (2.52)

.798

Florbetapir Standardized
PET SUVr Uptake Value
ratio

1.01 (0.16)

1.29 (0.13)

0.94 (0.07)

.000

MAC-Q

Total Score

26.32 (3.85)

26.6 (2.36)

25.97 (4.01)

.273

MMSE

Total Score

29.16 (1.0)

28.7 (1.25)

29.27 (0.93)

.118

ISLT
Total
Recall

Total words
recalled

25.78 (4.31)

24.10 (4.7)

25.89 (4.04)

.233

*Note: SUVr = standardized uptake value ratio; MAC-Q= Memory Complaint Questionnaire;
MMSE = Mini Mental State Examination; ISLT = International Shopping List Test
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Figure 1. Mean, range and standard deviation’s (SD) for fractal dimension (Df)
measurements, in the superficial vascular plexus within the macular region, for
individuals with elevated (preclinical AD, N = 10) vs. normal neocortical amyloid
aggregation (healthy controls, N = 28).

161

Figure 2. Mean, range and standard deviation’s (SD) for fractal dimension (Df)
measurements, in the superficial vascular plexus within the peripapillary region, for
individuals with elevated (preclinical AD, N = 10) vs. normal neocortical amyloid
aggregation (healthy controls, N = 38).
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Figure 3(a). Example of a linearized OCTA image for the superficial vascular plexus
from an individual who meets amyloid PET imaging criteria for preclinical AD

Figure 3(b). Example of a linearized OCTA image for the superficial vscular plexus
from a healthy control individual
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